Nucleic acid complex and pharmaceutical composition containing the same

A nucleic acid complex with a sugar ligand and oligonucleotide linker targets mannose or ASGPR receptors, addressing delivery challenges and enhancing intracellular uptake for therapeutic gene regulation.

CN114929729BActive Publication Date: 2024-12-03EISAI R&D MANAGEMENT CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180008225.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-30
Filing Date
2021-01-28
Publication Date
2024-12-03
Estimated Expiration
2041-01-28

AI Technical Summary

Technical Problem

Existing nucleic acid medicines face challenges in delivering nucleic acid drugs to cells due to their large size, low cell membrane permeability, and susceptibility to nucleases, which limits their therapeutic efficacy.

Method used

A nucleic acid complex is developed, comprising a sugar ligand, such as mannose or GalNac, linked to an oligonucleotide via a linker, which selectively targets and is taken up by cells expressing mannose receptors or ASGPR, enhancing intracellular delivery.

Benefits of technology

The nucleic acid complex effectively targets and is taken up by cells, enabling the regulation of gene expression and potential therapeutic benefits for various diseases by delivering nucleic acid drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114929729B_ABST
    Figure CN114929729B_ABST
Patent Text Reader

Abstract

The present invention discloses a nucleic acid complex represented by the following formula (I) or a pharmaceutically acceptable salt thereof [X is CH2 or O; Y is a sugar ligand containing mannose or GalNac; n is an integer from 1 to 8; Z is a group containing an oligonucleotide]. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a nucleic acid complex and a pharmaceutical composition containing the nucleic acid complex. Background Art

[0002] As nucleic acid medicines, antisense nucleic acids, decoy nucleic acids, ribozymes, aptamers, siRNA (small interfering RNA), miRNA (microRNA), messenger RNA (mRNA), etc. are known. Among them, nucleic acid medicines acting on mRNA are expected to be clinically applied to diseases that are currently difficult to treat because of their high versatility in controlling all genes in cells. That is, nucleic acid medicines are expected to become the next generation of medicines after low-molecular and antibody medicines. However, as problems with nucleic acid medicines, it can be listed that it is difficult to deliver nucleic acid medicines to the point of action, i.e., cells, due to the relatively large size of nucleic acid medicines, the significantly lower cell membrane permeability caused by the negative charge of the phosphate backbone, and the decomposition of siRNA caused by nucleases in the blood (non-patent literature 1).

[0003] In view of this problem, a method for solving the problem by adapting the delivery means to nucleic acid medicine is adopted. As one of the delivery means, a nucleic acid complex (complex nucleic acid) of a target ligand and a nucleic acid is reported. As a target ligand, a form of binding to a receptor expressed on the cell surface can be cited. For example, as a ligand relative to the asialoglycoprotein receptor (ASGPR) highly expressed in hepatocytes, a variety of nucleic acid complexes utilizing N-acetyl-D-galactosamine (GalNAc) etc. are reported (Patent Document 1, Patent Document 2, Patent Document 3, Non-Patent Document 2). Furthermore, as a drug carrier for the delivery of mannose receptors (CD206) highly expressed in immune cells such as macrophages or dendritic cells, mannose conjugates and mannosylated nucleic acid complexes (Patent Document 4) are reported. In addition, there are reports of modifying nucleic acid drugs with lipid-soluble compounds such as cholesterol and fatty acids to increase affinity with lipoproteins in plasma, thereby achieving delivery to cells expressing corresponding lipoprotein receptors (LDL (lowdensity lipoprotein) receptor, HDL (highdensity lipoprotein) receptor, scavenger receptor SRB1) (Non-patent document 3).

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: International Publication No. 2009 / 073809

[0007] Patent Document 2: International Publication No. 2014 / 179620

[0008] Patent Document 3: International Publication No. 2016 / 100401

[0009] Patent Document 4: International Publication No. 2018 / 004004

[0010] Non-patent literature

[0011] Non-patent document 1: Nature Reviews Drug Discovery. 8, 129-138 (2009).

[0012] Non-patent document 2: J. Am. Chem. Soc. 2014, 136, 16958-16961.

[0013] Non-patent document 3: Nucleic Acids Research, 2019, Vol. 47, No. 3, 1082-1096. Summary of the invention

[0014] [Problems to be solved by the invention]

[0015] Various target ligands and nucleic acid complexes containing the ligands have been proposed so far, but none has yet been found that can sufficiently improve the specific binding property with the receptor and enhance the intracellular absorption of the nucleic acid drug.

[0016] [Technical means to solve the problem]

[0017] The present inventors have conducted intensive studies to solve the above problems and have found a nucleic acid complex that is selectively taken up by cells. That is, the present invention relates to the following [1] to

[27] .

[0018] [1] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (I):

[0019]

[0020] [X is CH2 or O;

[0021] Y is a sugar ligand containing mannose or GalNac;

[0022] n represents an integer from 1 to 8;

[0023] Z is a group containing oligonucleotide].

[0024] [2] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (II):

[0025]

[0026] [Y is a sugar ligand containing mannose or GalNac;

[0027] Z is a group containing oligonucleotide].

[0028] [3] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (III):

[0029]

[0030] [Z is a group containing oligonucleotide].

[0031] [4] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (IV):

[0032]

[0033] [Z is a group containing oligonucleotide].

[0034] [5] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (V):

[0035]

[0036] [Z is a group containing oligonucleotide].

[0037] [6] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VI):

[0038]

[0039] [Z is a group containing oligonucleotide].

[0040] [7] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VII):

[0041]

[0042] [Z is a group containing oligonucleotide].

[0043] [8] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VIII):

[0044] [Z is a group containing oligonucleotide].

[0045] [9] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (IX):

[0046]

[0047] [Z is a group containing oligonucleotide].

[0048]

[10] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (X):

[0049]

[0050] [Z is a group containing oligonucleotide].

[0051]

[11] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (XI):

[0052]

[0053] [Z is a group containing oligonucleotide].

[0054]

[12] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (XII):

[0055]

[0056] [Z is a group containing oligonucleotide].

[0057]

[13] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (XIII):

[0058]

[0059] [Z is a group containing oligonucleotide].

[0060]

[14] A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (XIV):

[0061]

[0062] [Z is a group containing oligonucleotide].

[0063]

[15] The nucleic acid complex described in any one of [1] to

[14] above, wherein the oligonucleotide is a single strand.

[0064]

[16] The nucleic acid complex of

[15] above, wherein the oligonucleotide is bound via the 3' end.

[0065]

[17] The nucleic acid complex of

[15] above, wherein the oligonucleotide is bound via the 5' end.

[0066]

[18] The nucleic acid complex described in any one of [1] to

[14] above, wherein the oligonucleotide is double-stranded.

[0067]

[19] The nucleic acid complex of

[18] above, wherein the oligonucleotide is bound via the 3' end of one chain.

[0068]

[20] The nucleic acid complex of

[18] above, wherein the oligonucleotide is bound via the 5' end of one chain.

[0069]

[21] A pharmaceutical composition comprising the nucleic acid complex described in any one of [1] to

[20] above.

[0070]

[22] The pharmaceutical composition according to

[21] above, wherein the expression of a target gene in a cell is regulated.

[0071]

[23] The pharmaceutical composition according to

[22] above, wherein the cells are dendritic cells, macrophages or hepatocytes.

[0072]

[24] The nucleic acid complex according to any one of [1] to

[20] above, which is used in a method for regulating the expression of a target gene in a cell.

[0073]

[25] The nucleic acid complex as described in

[24] above, wherein the cell is a dendritic cell, a macrophage or a hepatocyte.

[0074]

[26] A method for regulating the expression of a target gene in a subject cell, comprising administering the nucleic acid complex described in any one of [1] to

[20] or the pharmaceutical composition described in

[21] to the subject.

[0075]

[27] The method as described in

[26] above, wherein the cells are dendritic cells, macrophages or hepatocytes.

[0076] [Effects of the Invention]

[0077] As shown in the following pharmacological tests, the nucleic acid complex of the present invention is selectively taken up by cells expressing mannose receptor or ASGPR. By administering a pharmaceutical composition containing the nucleic acid complex of the present invention to mammals (including humans), various related diseases may be cured. DETAILED DESCRIPTION

[0078] Hereinafter, the contents of the present invention will be described in detail.

[0079] Regarding the compounds in this specification, there are cases where the structural formula represents a certain isomer for convenience, but it is not limited to the description of the formula for convenience, and includes all geometric isomers, optical isomers, rotational isomers, stereoisomers, tautomers and other isomers and isomer mixtures generated in the structure of the compound, and any isomer can be a mixture containing each isomer in any ratio. Therefore, for example, the compounds in this specification may have optical isomers and racemates, which are not limited to any one in this specification, and can be a racemate, any one of the optically active bodies, or a mixture containing each optically active body in any ratio.

[0080] Furthermore, the compounds in this specification may exist in polymorphic forms, but are not limited to any one of them and may be a single substance of any crystalline form or a mixture. Furthermore, the compounds in this specification also include amorphous forms, and the compounds in this specification include anhydrates and solvates (especially hydrates).

[0081] The compounds in this specification also include isotope-labeled compounds of the compounds. Isotope-labeled compounds are the same as the compounds except that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Isotopes that can be incorporated into the compounds in this specification are, for example, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, phosphorus, sulfur, iodine, and chlorine, including 2 H. 3 H. 11 C. 14 C. 15 N. 18 O. 18 F and 35 S et al.

[0082] The "pharmaceutically acceptable salt" in the present specification is not particularly limited as long as it forms a salt with a compound, and specific examples thereof include salts such as acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.

[0083] Preferred examples of the acid addition salt include inorganic acid salts such as hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; or organic acid salts such as acetates, succinates, fumarates, maleates, tartrates, citrates, lactates, stearates, benzoates, methanesulfonates, p-toluenesulfonates, and benzenesulfonates.

[0084] Preferred examples of the metal salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; aluminum salts, zinc salts, and the like.

[0085] Preferred examples of the ammonium salt include salts of ammonium, tetramethylammonium, and the like.

[0086] Preferred examples of organic amine addition salts include addition salts of morpholine, piperidine, and the like.

[0087] Preferred examples of amino acid addition salts include addition salts of lysine, glycine, phenylalanine, aspartic acid, glutamic acid, and the like.

[0088] When the compound in the present specification is obtained in the form of a free form, it can be converted into a salt or a hydrate thereof which the compound can form according to a conventional method.

[0089] When the compound in the present specification is obtained in the form of a salt or a hydrate, it can be converted into a free form according to a conventional method.

[0090] In addition, various isomers (e.g., geometric isomers, optical isomers, rotational isomers, stereoisomers, tautomers, etc.) obtained with respect to the compounds in the present specification can be isolated by purification using a common separation method, such as recrystallization, a diastereomeric salt method, an enzyme cleavage method, and various chromatography methods (e.g., thin layer chromatography, column chromatography, gas chromatography, high performance liquid chromatography, etc.).

[0091] The pharmaceutical composition of the present invention can be prepared by mixing a pharmaceutically acceptable additive with the nucleic acid complex or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention can be prepared by a known method such as the method described in the General Principles of Preparations of the Seventeenth Revised Edition of the Japanese Pharmacopoeia.

[0092] The pharmaceutical composition of the present invention can be appropriately administered to patients according to its dosage form.

[0093] The dosage of the nucleic acid complex of the present invention varies depending on the degree of symptoms, age, sex, body weight, type of administration form or salt, specific type of disease, etc. Generally, in the case of adults, the dosage is converted to oligonucleotide, and is about 30μg to 10g, preferably 100μg to 1g per day for oral administration, and about 1μg to 1g, preferably 100μg to 300mg per day for injection, respectively, administered once or divided into multiple administrations.

[0094] The nucleic acid complex of the present invention is a nucleic acid complex in which a sugar ligand is bound to an oligonucleotide via a linker, and the sugar ligand contains O-, N-, or C-bound, preferably O-bound mannose or GalNac. That is, the nucleic acid complex of the present invention has a structure of (sugar ligand)-(linker)-(oligonucleotide).

[0095] In one embodiment, the nucleic acid complex contains two or more sugars, preferably three or four sugars. In one embodiment, the nucleic acid complex contains at least three mannoses or at least three GalNacs, and the nucleic acid complexes can be delivered by targeting macrophages or hepatocytes, respectively.

[0096] <About Sugar Ligand>

[0097] Mannose receptors are highly expressed in cells that highly express CD206, such as macrophages or dendritic cells. Mannose conjugates and mannosylated drug carriers express high binding affinity for CD206 and have been successfully used to deliver drug molecules, such as oligonucleotides, to cells such as macrophages or dendritic cells.

[0098] ASGPR is highly expressed in specific cells such as hepatocytes. GalNac conjugates and GalNac-modified drug carriers express high binding affinity to ASGPR and have been successfully used to deliver drug molecules, such as oligonucleotides, to cells such as hepatocytes.

[0099] Sugar ligand means a group derived from a sugar that can bind to a receptor expressed in a target cell, and one preferred sugar ligand in the nucleic acid complex of the present invention includes the following structures: The wavy line means a bond to a linker.

[0100]

[0101]

[0102] <About Oligonucleotide>

[0103] As the oligonucleotide in the nucleic acid complex of the present invention, oligonucleotides known to be used as nucleic acid drugs can be used. In this specification, nucleic acid drugs refer to nucleotides used in the form of antisense nucleic acids, decoy nucleic acids, ribozymes, siRNA, miRNA, antimiRNA, and mRNA.

[0104] Furthermore, the oligonucleotide may be a single-stranded or double-stranded oligonucleotide.

[0105] The linker and oligonucleotide in the nucleic acid complex of the present invention can be bound to the nucleotide of the oligonucleotide, for example, at the 3' end or 5' end of the oligonucleotide. When the oligonucleotide is double-stranded, the linker is preferably bound to the 3' end or 5' end of the sense strand constituting the double-stranded nucleic acid, but is not limited to this binding.

[0106] The number of linkers to which the oligonucleotide in the nucleic acid complex is bound is not limited to one, and may be two or more.

[0107] In several embodiments, specific bases may be included in the overhangs, or modified nucleotides or nucleotide substitutions may be included in the single-stranded overhangs (eg, 5' overhangs or 3' overhangs, or both), for example, to improve stability.

[0108] The oligonucleotide constituting the nucleic acid complex of the present invention may be in any form as long as it has the ability to control the expression of the target gene when introduced into mammalian cells, and a single-stranded oligonucleotide or a double-stranded oligonucleotide can be used as appropriate.

[0109] As an oligonucleotide, any molecule may be used as long as it is a polymer of a nucleotide or a molecule having the same function as a nucleotide, for example, DNA as a polymer of deoxyribonucleotides, RNA as a polymer of ribonucleotides, and chimeric nucleic acids as a polymer of DNA and RNA. In addition, in DNA, RNA and chimeric nucleic acids, at least one nucleotide such as a deoxyribonucleotide or a ribonucleotide may be replaced by a molecule having the same function as a nucleotide. Furthermore, uracil (U) in RNA may be univocally renamed thymine (T) in DNA.

[0110] Examples of molecules having functions equivalent to those of nucleotides include nucleotide derivatives obtained by modifying nucleotides. For example, molecules obtained by modifying deoxyribonucleotides or ribonucleotides can be appropriately used in order to improve or stabilize nuclease resistance compared to DNA or RNA, to increase affinity with complementary nucleic acid chains, to increase cell permeability, or to visualize them.

[0111] Examples of nucleotide derivatives include nucleotides in which at least one of the sugar part, the phosphodiester bond and the base is modified, such as sugar part-modified nucleotides, phosphodiester bond-modified nucleotides and base-modified nucleotides.

[0112] The sugar-modified nucleotide may be any nucleotide as long as a part or the whole of the chemical structure of the sugar of the nucleotide is modified or substituted with any substituent or substituted with any atom, but 2'-modified nucleotides are preferably used.

[0113] As 2'-modified nucleotides, for example, 2'-OH groups of ribose are substituted with a substituent selected from the group consisting of OR, R, R'OR, SH, SR, NH2, NHR, NR2, N3, CN, F, Cl, Br and I (R is an alkyl group or an aryl group, preferably an alkyl group having 1 to 6 carbon atoms, and R' is an alkylene group, preferably an alkylene group having 1 to 6 carbon atoms). As 2'-modifications, substitutions with F, methoxy and ethoxy groups are preferably mentioned. In addition, 2'-modified nucleotides, i.e., locked nucleic acids, in which the oxygen atom at the 2' position of ribose and the carbon at the 4' position are bridged by a methylene group may also be mentioned.

[0114] The phosphodiester bond-modified nucleotide may be any nucleotide as long as a part or all of the chemical structure of the phosphodiester bond of the nucleotide is modified or substituted with any substituent, or substituted with any atom. Examples thereof include nucleotides in which the phosphodiester bond is substituted with a phosphorothioate bond, nucleotides in which the phosphodiester bond is substituted with a phosphorodithioate bond, nucleotides in which the phosphodiester bond is substituted with an alkylphosphonate bond, nucleotides in which the phosphodiester bond is substituted with an aminophosphoester bond, and the like. Preferably, a nucleotide in which the phosphodiester bond is substituted with a phosphorothioate bond can be mentioned.

[0115] Oligonucleotides also include those in which a part or all of the atoms in the molecule are substituted with atoms having different mass numbers (isotopes).

[0116] In one aspect, the oligonucleotides in the nucleic acid complexes of the invention modulate the expression of a target gene in a cell.

[0117] In one aspect, the oligonucleotide in the nucleic acid complex of the invention is bound to a ligand via a linker (also referred to as a linker ligand).

[0118] <About connector>

[0119] As the "linker" in the present invention, any linker that can be used as a nucleic acid complex can be used.

[0120] As examples of the joint structure, for example, structures disclosed in International Publication No. 2009 / 073809, International Publication No. 2013 / 075035, and International Publication No. 2015 / 105083 may be adopted.

[0121] In one embodiment, the linker comprises at least one cleavable binding group.

[0122] The so-called cleavable binding group is a group that is very stable outside the cell, but is cleaved once inside the target cell to release the part bound to the linker.

[0123] For example, a cleavable binding group based on phosphate can be cleaved by an agent that decomposes or hydrolyzes the phosphate group. Examples of enzymes that cleave the phosphate group in cells are phosphatases and the like. A preferred embodiment of the binding group based on phosphate is -OP(O)(OH)-O- or OP(S)(OH)-O-.

[0124] An embodiment of the linker is any one of the following structures, wherein X and Y exist independently, X represents CH2 or O, Y represents a sugar ligand, Z represents a group containing an oligonucleotide, and n represents an integer from 1 to 8.

[0125]

[0126] Example

[0127] The nucleic acid complex of the present invention can be produced, for example, by the method described in the following preparation examples, and the effect of the compound can be confirmed by the method described in the following test examples. However, these are illustrative, and the present invention is not limited to the following specific examples in any case, and can be changed within the scope of the present invention. The embodiments of the present invention can be produced using synthetic chemistry techniques known to those skilled in the art.

[0128] In addition, the abbreviations used in this specification are commonly used abbreviations well known to those skilled in the art. The following abbreviations are used in this specification.

[0129] Cbz: benzyloxycarbonyl

[0130] CTC: 2-Chlorotrityl chloride

[0131] DCE: 1,2-dichloroethane

[0132] DCM: dichloromethane

[0133] DIPEA: N,N-diisopropylethylamine

[0134] DMF: N,N-dimethylformamide

[0135] DMSO: dimethyl sulfoxide

[0136] EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

[0137] EtOAc: ethyl acetate

[0138] ESI: electrospray ionization

[0139] Fmoc: 9-fluorenylmethoxycarbonyl

[0140] HBTU: 1-[Bis(dimethylamino)methylene]-1H-benzotriazolium 3-oxide hexafluorophosphate

[0141] HOBT: 1-Hydroxybenzotriazole

[0142] IMS: Industrial Modified Alcohols

[0143] MALDI-TOF-MS: matrix-assisted laser desorption ionization-time of flight mass spectrometry

[0144] MeOH: Methanol

[0145] MTBE: Methyl tert-butyl ether

[0146] NaOMe: Sodium Methanol

[0147] TFA: trifluoroacetic acid

[0148] 1 H-NMR: Proton Nuclear Magnetic Resonance Spectroscopy

[0149] MS: mass spectrometry

[0150] HPLC: High Performance Liquid Chromatography

[0151] In the following Examples and Production Examples, "room temperature" generally means about 10° C. to about 35° C. % means weight or volume percentage unless otherwise specified.

[0152] Chemical shifts for proton NMR spectra are reported in δ units (ppm) relative to tetramethylsilane, coupling constants are reported in Hertz (Hz). Modes are s: singlet, d: doublet, t: triplet, q: quartet, quin: quintet, m: multiplet, br: broad, br.s: broad singlet.

[0153] For silica gel column chromatography, silica gel was used: Silica Gel 60 (70-230 mesh, or 230-400 mesh ASTM) manufactured by Merck, PSQ60B manufactured by Fuji Silysia Chemical, or a prepacked column (column: Hi-Flash manufactured by YAMAZEN) TM Column (Silicagel), or Biotage manufactured by Biotage TM SNAP Ultra Silica Cartridge).

[0154] The names of the compounds were those shown in "E-Notebook" 12th or 13th edition (PerkinElmer) or "Marvin Sketch" 16th edition (ChemAxon) except for commonly used reagents.

[0155] The following production examples are used as references, and the production can be carried out by methods known to those skilled in the art.

[0156] Synthesis process of compound 6

[0157]

[0158] Synthesis of compound 2

[0159]

[0160] DMF (200 mL) was added to acetic acid hydrazine (5.19 g, 56.4 mmol), and after stirring at 55 ° C, the reaction mixture was cooled to 15 ° C, 1-O, 2-O, 3-O, 4-O, 6-O-pentaacetyl-β-D-mannose (Compound 1) (20.0 g, 51.2 mmol) was added, and stirred at 15 ° C for 16 hours. The reaction mixture was added to water and extracted with EtOAc. The combined organic layer was washed with saturated brine, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Compound 2 (14.3 g).

[0161] 1 H-NMR (400MHz, CDCl3) δ (ppm): 1.97-2.00 (m, 3H), 2.03 (s, 3H), 2.08 (s, 3H), 2.14 ( s,3H),4.11-4.15(m,1H),4.16-4.32(m,3H),5.14-5.34(m,3H),5.37-5.45(m,1H).

[0162] Synthesis of compound 3

[0163]

[0164] Compound 2 (5.00 g, 14.4 mmol), 2,2,2-trichloroacetonitrile (20.7 g, 143 mmol) and Cs2CO3 (5.14 g, 15.8 mmol) were added to DCM (50 mL) and stirred at 25 ° C for 2 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50: 1-20: 1 petroleum ether / EtOAc) to obtain compound 3 (2.70 g).

[0165] 1 H-NMR (400MHz, CDCl3) δ (ppm): 2.01 (s, 3H), 2.04 (s, 2H), 2.08 (d, J = 6.8Hz, 6H), 2.20 (s, 3H), 4.15-4.2 2(m,2H),4.24-4.32(m,1H),5.37-5.42(m,2H),5.46-5.49(m,1H),6.28(d,J=1.8Hz,1H),8.79(s,1H).

[0166] Synthesis of compound 4

[0167]

[0168] Compound 3 (14.0 g, 28.4 mmol), 6-(Cbz-amino)-1-hexanol (8.57 g, 34.1 mmol) and molecular sieve 4A (10.0 g) were added to DCM (140 mL) and stirred at 0 ° C for 30 minutes. Then, trimethylsilyl trifluoromethanesulfonate (6.32 g, 28.4 mmol) was added dropwise to the reaction mixture at -65 ° C, and the reaction mixture was stirred at 25 ° C for 16 hours. The reaction mixture was diluted with DCM, filtered, and the filtrate was washed with saturated sodium bicarbonate aqueous solution, water and brine, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50: 1-20: 1 petroleum ether / EtOAc) to obtain compound 4 (7.50 g).

[0169] Synthesis of compound 5

[0170]

[0171] Compound 4 (7.50 g, 12.9 mmol) was dissolved in MeOH (300 mL), and NaOMe (2.79 g, 51.6 mmol) was added, and the mixture was reacted at room temperature for 3 hours. A portion of the reaction mixture was concentrated, poured into cold water, and acetic acid was added until pH = 5. The crude product was purified by silica gel column chromatography (50:1-20:1 DCM / MeOH) to obtain compound 5 (3.90 g).

[0172] 1 H-NMR (400MHz, CDCl3) δ (ppm): 1.26-1.63 (m, 8H), 3.14 (d, J = 6.3Hz, 2H), 3.34 (d, J = 8.8Hz, 1H), 3.54- 3.74(m,2H),3.80-4.01(m,4H),4.78(s,1H),5.01-5.12(m,2H),5.16-5.47(m,6H),7.28-7.41(m,5H).

[0173] Synthesis of compound 6

[0174]

[0175] MeOH (40 mL) and compound 5 (3.90 g, 9.43 mmol) were added to dry 10% palladium-carbon (0.40 g), and the mixture was stirred at 25° C. under hydrogen pressure (50 psi) for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain compound 6 (1.50 g).

[0176] 1H-NMR (400MHz, MeOD) δ (ppm): 1.38-1.49 (m, 4H), 1.61 (dquin, J = 13.3, 6.9, 6.9, 6.9, 6.9Hz, 4H) ,2.73-2.88(m,2H),3.31(dt,J=3.3,1.6Hz,1H),3.43(dt,J=9.7,6.1Hz,1H),3.48-3.89(m,8H).

[0177] Synthesis of compound 8

[0178]

[0179] To a DMF (3 mL) solution of 6-azidohexanoic acid (Compound 7) (50.2 mg, 319 μmol) and Compound 6 (268 mg, 959 μmol) were added HOBt (129 mg, 959 μmol), DIPEA (248 mg, 1.92 mmol) and EDCI (183 mg, 959 μmol), and the mixture was stirred at 25° C. for 3 hours. The reaction mixture was purified by preparative HPLC (TFA conditions) to obtain Compound 8 (20.1 mg).

[0180] 1 H-NMR (400MHz, DMSO-d6) δ (ppm): 1.24-1.54 (m, 14H) 2.04 (t, J = 7.40Hz, 2H) 3. 00(q,J=6.53Hz,2H)3.23-3.40(m,12H)3.55-3.66(m,2H)4.57(s,1H)7.75(br s,1H)

[0181] Synthesis process of compound 11

[0182]

[0183] Synthesis of compound 10

[0184]

[0185] DCM (30 mL) and DIPEA (258 mg, 2.00 mmol) were added to a mixture containing CTC resin (0.50 g, 0.50 mmol, 1.00 mmol / g) and N-[(9H-fluorene-9-ylmethoxy)carbonyl]-glutamic acid 5-tert-butyl ester (Compound 9) (212 mg, 0.50 mmol), and the reaction mixture was stirred for 2 hours. MeOH (0.2 mL) was added to the reaction mixture and stirred for 30 minutes. 6-azidohexanoic acid (Compound 7) (118 mg, 0.75 mmol), DIPEA (258 mg, 2.00 mmol), HBTU (270 mg, 712 umol) and DMF (3 mL) were added to the reaction mixture and stirred at 25° C. for 1 hour. 90% TFA / 10% DCM was added to the reaction mixture and stirred for 2 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain Compound 10 (110 mg).

[0186] Synthesis of compound 11

[0187]

[0188] HOBt (141 mg, 1.05 mmol), DIPEA (270 mg, 2.10 mmol) and EDCI (200 mg, 1.05 mmol) were added to a DMF (3 mL) solution of compound 10 (50.0 mg, 174 μmol) and compound 6 (292 mg, 1.05 mmol). The reaction mixture was stirred at 25 ° C. for 16 hours. Purification was performed by preparative HPLC (TFA conditions) to obtain compound 11 (18.1 mg).

[0189] 1 H-NMR(400MHz,DMSO-d6)δ(ppm):1.16-1.56(m,24H),1.62-1.73(m,1H),1.76-1.87(m,1 H),2.00-2.07(m,2H),2.09-2.15(m,2H),2.95-3.07(m,4H),3.22-3.41(m,18H),3.65(br s, 6H), 4.10-4.19 (m, 1H), 4.57 (d, J = 1.00Hz, 2H), 7.74-7.93 (m, 3H).

[0190] Synthesis of compound 12

[0191]

[0192] DCM (20 mL) and DIPEA (516 mg, 4.00 mmol) were added to CTC resin (1.00 g, 1.00 mmol, 1.00 mmol / g) and N-[(9H-fluoren-9-ylmethoxy)carbonyl]-glutamic acid 5-tert-butyl ester (Compound 9) (511 mg, 1.20 mmol), and the reaction mixture was stirred for 2 hours while nitrogen (N2) was passed through. MeOH (1 mL) was added to the reaction mixture, and the mixture was stirred for 30 minutes. A 20% piperidine solution in DMF (30 mL) was added to the reaction mixture, and the mixture was stirred for 30 minutes. The resin was washed with DMF, and a solution of N-Fmoc-glutamic acid 1-tert-butyl ester (851 mg, 2.00 mmol), HBTU (720 mg, 1.90 mmol) and DIPEA (516 mg, 4.00 mmol) in DMF (5 mL) was added, and the mixture was stirred at 25°C for 1 hour. A 20% piperidine solution in DMF (30 mL) was added, stirred for 30 minutes, and the resin was washed with DMF. Subsequently, a DMF (5 mL) solution of 6-azidohexanoic acid (Compound 7) (0.30 g, 1.91 mmol), HBTU (720 mg, 1.90 mmol) and DIPEA (516 mg, 4.00 mmol) was added, stirred at 25°C for 1 hour, and the resin was washed with DMF and washed with MeOH, and dried under reduced pressure. 50% TFA / 50% DCM was added to the obtained residue (0.60 g), stirred for 2 hours, and the reaction mixture was concentrated under reduced pressure to obtain Compound 12 (240 mg).

[0193] Synthesis of compound 13

[0194]

[0195] The synthesis of compound 13 was carried out according to the synthesis method of compound 12, except that azido-PEG8-acid (CAS No. 1214319-92-2) was used instead of 6-azidohexanoic acid to obtain compound 13 (350 mg).

[0196] 1 H-NMR (400MHz, CDCl3) δ (ppm): 2.01 (s, 2H), 2.18 (s, 2H), 2.32-2.63 (m, 6H) ,3.40(t,J=5.0Hz,2H),3.54-3.71(m,32H),4.49(s,2H),7.67-8.03(m,2H).

[0197] Synthesis of compound 14

[0198]

[0199] DIPEA (996 mg, 7.70 mmol), HOBt (520 mg, 3.85 mmol) and EDCI (738 mg, 3.85 mmol) were added to a DMF (0.5 mL) solution of compound 12 (0.20 g, 481 μmol) and compound 7 (1.08 g, 3.85 mmol). The reaction mixture was stirred at 25° C. for 16 hours and purified by preparative HPLC (TFA conditions) to obtain compound 14 (103 mg).

[0200] 1 H-NMR(400MHz,MeOD)δ(ppm):1.26-1.72(m,32H),1.82-1.97(m,2H),2.03-2.13(m,2H),2.22-2.41(m,6H),3.14-3.24( m, 6H), 3.37-3.47 (m, 3H), 3.49-3.55 (m, 3H), 3.60 (t, J = 9.5Hz, 3H), 3.65-3.86 (m, 15H), 4.22-4.42 (m, 2H), 4.73 (s, 3H).

[0201] Synthesis of compound 15

[0202]

[0203] DIPEA (570 mg, 4.41 mmol), HOBT (298 mg, 2.20 mmol) and EDCI (423 mg, 2.20 mmol) were added to a solution of compound 13 (0.20 g, 275 μmol) and compound 7 (616 mg, 2.20 mmol) in DMF (0.5 mL), and the reaction mixture was stirred at 25° C. for 16 hours. The reaction mixture was purified by preparative HPLC (TFA conditions) to obtain compound 15 (127 mg).

[0204] 1 H-NMR(400MHz,MeOD)δ(ppm):1.23-1.68(m,24H),1.78-1.95(m,2H),2.04-2.19(m,2H),2.23-2.31(m,2H),2.33-2.42(m,2H),2 .48-2.60(m,2H),3.10-3.26(m,6H),3.35-3.46(m,5H),3.48-3.56(m,3H),3.57-3.84(m,50H),4.23-4.41(m,2H),4.73(s,3H).

[0205] Synthesis process of compound 17

[0206]

[0207] Synthesis of compound 16

[0208]

[0209] DCM (30 mL) and DIPEA (258 mg, 2.00 mmol) were added to CTC resin (0.50 mmol, 0.50 g, 1.00 mmol / g) and N-[(9H-fluoren-9-ylmethoxy)carbonyl]-glutamic acid 5-tert-butyl ester (Compound 9) (212 mg, 0.50 mmol). The reaction mixture was stirred for 2 hours, and then MeOH (0.2 mL) was added and stirred for 30 minutes. To the reaction mixture, a solution of HBTU (360 mg, 950 μmol) and DIPEA (258 mg, 2.00 mmol) in DMF (3 mL) and N-Fmoc-glutamic acid 1-tert-butyl ester (425 mg, 1.00 mmol) were added, and after stirring at 25° C. for 1 hour, a solution of N-Fmoc-glutamic acid 1-tert-butyl ester (425 mg, 1.00 mmol), HBTU (360 mg, 950 μmol) and DIPEA (258 mg, 2.00 mmol) in DMF (3 mL) were added, and the mixture was added at 25° C. for 1 hour. Subsequently, 6-azidohexanoic acid (Compound 7) (118 mg, 750 μmol), HBTU (360 mg, 950 μmol), and DIPEA (258 mg, 2.00 mmol) were added, and the mixture was stirred for 1 hour. 90% TFA / 10% DCM was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain Compound 16 (200 mg).

[0210] Synthesis of compound 17

[0211]

[0212] To a solution of compound 16 (50.0 mg, 91.8 μmol) and compound 7 (256 mg, 918 μmol) in DMF (3 mL) were added HOBt (124 mg, 918 μmol), DIPEA (237 mg, 1.84 mmol) and EDCI (176 mg, 918 μmol), and the reaction mixture was stirred at 25° C. for 16 hours. The reaction mixture was purified by preparative HPLC (TFA conditions) to obtain compound 17 (18.2 mg).

[0213] 1H-NMR(400MHz,DMSO-d6)δ(ppm):1.19-1.56(m,40H),1.66(br s,3H),1.83(br s,3H),2.00-2.15(m,7H),2.94-3.05(m,8H),3.29(br d,J=5.02Hz,24H),3.52-3.71(m,24H),4.13(br s,3H),4.57(s,4H),7.74-7.99(m,7H).

[0214] Synthesis process of compounds 21 and 22

[0215]

[0216] Synthesis of compound 19

[0217]

[0218] DCE (120 mL) was added to a mixture of galactosamine pentaacetate compound 18 (12.0 g, 30.8 mmol), 6-(Cbz-amino)-1-hexanol (10.3 g, 41.1 mmol) and ZnCl2 (5.60 g, 41.1 mmol) (dried under reduced pressure at 110°C for 1 hour before use), and the reaction mixture was stirred at 70°C for 3 hours. The reaction mixture was diluted with EtOAc and an aqueous sodium bicarbonate solution, the mixture was stirred for 10 minutes, filtered through diatomaceous earth (registered trademark), and washed with EtOAc. The filtrate was washed with water and brine. The aqueous layer was extracted with EtOAc, the organic layer was dried with sodium sulfate, filtered, concentrated under reduced pressure, and the residue obtained was purified by silica gel column chromatography (2:1 petroleum ether / EtOAc) to obtain compound 19 (14.0 g).

[0219] 1H-NMR (400MHz, CDCl3) δ (ppm): 1.35 (d, J = 3.8Hz, 4H), 1.45-1.66 (m, 4H), 1.77 (s, 2H), 1.94 (s, 3H), 2.00(s,3H),2.05(s,3H),2.14(s,3H),3.20(qq,J=13.4,6.8Hz,2H),3.48(dt,J=9.6,6.5Hz,1H),3 .79-4.03(m,3H),4.08-4.19(m,2H),4.65(d,J=8.3Hz,1H),4.90(s,1H),5.04-5.17(m,2H),5.26(d d,J=11.2,3.1Hz,1H),5.30(s,1H),5.34(d,J=2.8Hz,1H),5.94(d,J=8.8Hz,1H),7.28-7.42(m,5H).

[0220] Synthesis of compound 20

[0221]

[0222] MeOH (300 mL) and NaOMe (2.79 g, 51.7 mmol) were added to compound 19 (7.50 g, 12.9 mmol), and the mixture was stirred at room temperature for 3 hours. A portion of the reaction mixture was concentrated and poured into cold water, and acetic acid was added until pH = 5. The crude product was then purified by silica gel column chromatography (50:0-50:1 DCM / MeOH) to obtain compound 20 (4.00 g).

[0223] 1 H-NMR (400MHz, MeOD) δ (ppm): 1.19-1.35 (m, 4H), 1.40-1.56 (m, 4H), 1.93 (s, 2H), 3.06 (t, J = 7.0Hz, 2H), 3.27 (dt, J = 3.3, 1.6Hz, 1H), 3.31 (s, 1H) ),3.37-3.49(m,2H),3.55(dd,J=10.8,3.3Hz,1H),3.65-3.76(m,2H),3 .78-3.94(m,3H),4.31(d,J=8.5Hz,1H),5.02(s,2H),7.17-7.44(m,5H).

[0224] Synthesis of compound 21

[0225]

[0226] MeOH (25 mL) and compound 20 (2.40 g, 5.28 mmol) were added to dry 10% palladium-carbon (240 mg) under argon atmosphere, and stirred at 25° C. for 3 hours under hydrogen pressure (50 psi). The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain compound 21 (0.66 g).

[0227] 1 H-NMR (400MHz, MeOD) δ (ppm): 1.30-1.44 (m, 4H), 1.52-1.66 (m, 4H), 1.98 (s, 3H), 2.76-2.90 (m, 2H), 3.31 (dt, J = 3.3, 1. 6Hz,2H),3.44-3.51(m,2H),3.58(dd,J=10.8,3.3Hz,1H),3.73-3.78(m,2H),3.82-3.95(m,3H),4.34(d,J=8.5Hz,1H).

[0228] Synthesis of compound 22

[0229]

[0230] Ethanol (6 mL) and 10% palladium-carbon (50% water-containing) (42 mg) were added to compound 19 (202 mg, 0.35 mmol), and stirred at room temperature for 3 hours under a hydrogen atmosphere. The reaction mixture was filtered through celite (registered trademark) and washed with ethanol. The filtrate was concentrated under reduced pressure to obtain compound 22 (159 mg).

[0231] 1 H-NMR(600MHz,DMSO-d6)δ(ppm):0.64(br s,1H)1.27(br s,5H)1.33-1.52(m,4H)1.67(br s,1H)1.80(s,3H)2.61(br t,J=6.88Hz,2H)3.40-3.60(m,5H)3.58-3.77(m,4H)4.23(br d,J=8.25Hz,1H)4.31-4.97(m,5H)7.53-7.71(m,1H); MS(ESI+): m / z 321[M+H]+.

[0232] Synthesis of compound 23

[0233]

[0234] DIPEA (485 mg, 3.76 mmol), HOBt (254 mg, 1.88 mmol) and EDCI (360 mg, 1.88 mmol) were added to a solution of compound 12 (602 mg, 1.88 mmol) and compound 21 (601 mg, 1.88 mmol) in DMF (0.5 mL), and the reaction mixture was stirred at 25° C. for 16 hours. The residue was purified by preparative HPLC (TFA conditions) to obtain compound 23 (104 mg).

[0235] 1 H-NMR (400MHz, MeOD) δ (ppm): 1.29-1.70 (m, 32H), 1.82-2.01 (m, 11H), 2.08 (s, 2H), 2.22-2.38 (m, 8H), 3.18 (d, J =6.3Hz,6H),3.42-3.52(m,6H),3.60(d,J=10.5Hz,3H),3.71-3.95(m,14H),4.28(s,1H),4.36(d,J=8.3Hz,3H).

[0236] Synthesis of compound 24

[0237]

[0238] In the same manner as in the synthesis of Compound 23, Compound 24 was obtained by using Compound 16 instead of Compound 12.

[0239] 1 H-NMR (600MHz, DMSO-d6) δ (ppm): 1.15-1.59 (m, 44H) 1.68 (br d, J=9.90Hz, 3H) 1.79 (s, 12H) 1.82-1.92 (m, 5H) 1.97-2.22 (m, 9H) 3.02 (br d,J=5.50Hz,10H)3.32-3.58(m,19H)3.61-3.72(m,13H)4.06-4.27(m,8H)4.43(br s,4H)4.46-4.59(m,9H)7.59(br d,J=8.80Hz,4H)7.74(br s,1H)7.83(br s,3H)7.89(br s,3H); MS(ESI+): m / z 1754[M+H]+.

[0240] Synthesis process of compound 28

[0241]

[0242] Synthesis of compound 25

[0243]

[0244] DCM (30 mL) was added to a mixture containing CTC resin (1.33 mmol / g, 0.375 g, 0.50 mmol) and compound 9 (212 mg, 0.50 mmol), and DIPEA (0.35 mL, 2.00 mmol) was added dropwise, and the reaction solution was stirred for 2 hours. MeOH (0.2 mL, 4.94 mmol) was added to the reaction solution and stirred for 35 minutes. A 20% piperidine solution in DMF (15 mL) was added to the reaction solution and stirred for 30 minutes. The reaction mixture was filtered and the obtained solid was washed with DMF. Then, N-Fmoc-D-glutamic acid 1-tert-butyl ester (213 mg, 0.499 mmol), N-Fmoc-L-glutamic acid 1-tert-butyl ester (213 mg, 0.499 mmol), HBTU (360 mg, 0.949 mmol), DMF (3 mL) and DIPEA (0.35 mL, 2.00 mmol) were added, and nitrogen was passed through the reaction mixture and stirred for 1 hour. A 20% piperidine solution in DMF (15 mL) was added and stirred for 30 minutes. The resin was then washed with DMF. Then, N-Fmoc-D-glutamic acid 1-tert-butyl ester (213 mg, 0.499 mmol), N-Fmoc-L-glutamic acid 1-tert-butyl ester (213 mg, 0.499 mmol), HBTU (360 mg, 0.949 mmol) and DMF (3 mL) were added, and DIPEA (0.35 mL, 2.00 mmol) was slowly added dropwise. The reaction mixture was purged with nitrogen and stirred for 80 minutes. The resin was then washed with DMF and MeOH and dried under reduced pressure. 50% TFA / 50% DCM was added to the obtained residue, stirred for 2 hours and filtered, and the filtrate was concentrated under reduced pressure to obtain compound 25 (307.3 mg).

[0245] MS (ESI) M / Z: 610 [M+H] +

[0246] 1 H-NMR(600MHz,DMSO-d6)δ(ppm):1.77(m,5H),1.94(m,3H),2.12-2.23(m,6H),2.26(m,2H),2.38(br t,J=7.34Hz,2H),4.13-4.21(m,3H),5.09(s,2H),7.30-7.40(m,5H),8.05-8.15(m,3H).

[0247] Synthesis of compound 26

[0248]

[0249] HOBt (52.8 mg, 0.344 mmol), DIPEA (0.12 mL, 0.689 mmol) and EDCI (66.0 mg, 0.344 mmol) were added to a DMF (2 mL) solution of compound 22 (154 mg, 0.344 mmol) and compound 25 (21.0 mg, 0.034 mmol). The reaction mixture was stirred at room temperature for 18 hours, and water, EtOAc and a small amount of methanol were added for extraction, and the organic layer was dried over sodium sulfate. After filtration, it was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain compound 26 (16.7 mg).

[0250] MS (ESI) M / Z: 1162 [M+2H] +

[0251] 1 H-NMR(600MHz,DMSO-d6)δ(ppm):1.23(br s,16H),1.31-1.41(m,8H),1.41-1.48(m,8H),1.60-1.73(m,4H),1.77(s,12H),1.78-1.87(m,4H),1.89(s,12H),1 .99(s,12H),2.01-2.07(m,2H),2.10(s,12H),2.11-2.21(m,6H),2.33-2.37(m,2H),2.95-3.07(m,8H),3.37-3.43 (m,4H),3.65-3.72(m,4H),3.82-3.90(m,4H),3.98-4.05(m,12H),4.09-4.20(m,3H),4.48(d,J=8.44Hz,4H),4.97 (dd,J=11.19,3.12Hz,4H),5.08(s,2H),5.21(d,J=3.30Hz,4H),7.30-7.39(m,5H),7.80(m,8H),7.86-7.95(m,3H).

[0252] Synthesis of compound 27

[0253]

[0254] 10% palladium-carbon (50% water-containing product) (5.3 mg) was added to a solution of compound 26 (19.0 mg, 8.18 μmol) in ethanol (3 mL). The reaction mixture was stirred at room temperature for 3 hours under a hydrogen atmosphere. The reaction mixture was filtered through celite (registered trademark) and washed with ethanol. The filtrate was concentrated under reduced pressure to obtain compound 27 (19.6 mg).

[0255] 1 H-NMR(600MHz,DMSO-d6)δ(ppm):1.24(br s,22H),1.30-1.40(m,8H),1.45(br s,8H),1.61-1.74(m,4H),1.77(s,12H),1.80-1.87(m,2H),1.89(s,12H),1.99(s,12H),2.01-2.07(m,2H),2.10(s,12H),2 .12-2.25(m,4H),2.93-3.06(m,8H),3.36-3.46(m,4H),3.64-3.72(m,4H),3.82-3.91(m,4H),3.98-4.20(m,16H),4.50(br d,J=8.07Hz,4H),4.94-5.02(m,4H),5.21(d,J=2.93Hz,4H)7.73-8.03(m,11H).

[0256] Synthesis of compound 28

[0257]

[0258] Triethylamine (8.7 μL, 62 μmol) and pentafluorophenyl trifluoroacetate (5.4 μL, 31 μmol) were added to a DMF (2 mL) solution of compound 27 (17.4 mg, 7.79 μmol) under a nitrogen atmosphere, and the reaction mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction solution and extracted with EtOAc. The organic layer was washed with saturated sodium bicarbonate, sodium bisulfate and saturated brine. After concentration under reduced pressure, the residue was wet-triturated with pentane, filtered and dried at 40 degrees under reduced pressure to obtain compound 28 (11.72 mg).

[0259] MS (ESI) M / Z: 1200 [M+2H] +

[0260] 1H-NMR(600MHz,DMSO-d6)δ(ppm):1.24(br s,20H),1.31-1.40(m,8H),1.41-1.49(m,8H),1.61-1.72(m,2H),1.77(s,12H),1.79-1.86(m,2H),1.89 (s,12H),1.99(s,12H),2.01-2.07(m,2H),2.10(s,12H),2.12-2.21(m,4H),2.25-2.31(m,2H),2.80(br t,J=7.34Hz,2H),2.95-3.08(m,8H),3.37-3.43(m,4H),3.65-3.72(m,4H),3.82-3.90(m,4H),3.97-4.06(m,12H),4.10-4.22 (m,3H),4.48(d,J=8.44Hz,4H),4.97(dd,J=11.00,2.93Hz,4H),5.21(d,J=2.93Hz,4H),7.70-7.86(m,8H),7.86-8.01(m,3H).

[0261] Examples 1 to 7: Synthesis of Nucleic Acid Complexes 1 to 7

[0262] SEQ-1 and SEQ-2 were commissioned to be synthesized by JEEN DESIGN. Sodium tetraborate buffer (pH 8.5, final concentration 40mM) was added to SEQ-2 (1.3μmol), and DBCO-NHS ester (Dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-N-hydroxysuccinimide ester) (CAS No. 1353016-71-3, 60μmol) dissolved in DMSO was added and stirred at room temperature for 15 minutes. After adding water to the reaction solution, gel filtration purification was performed using a PD-10 column (GE Healthcare). Amicon Ultra 3K (Millipore) was then used for purification and concentration to obtain a crude product (SEQ-3). Triethylammonium acetate (pH 7.0, final concentration 50 mM) was added to the crude product (40 nmol), and compounds 8, 11, 14, 15, 17, 23, 24 (400 nmol) dissolved in water were added respectively, and stirred at room temperature for 15 minutes. The reaction solution was purified by gel filtration using a PD-10 column (GE Healthcare). Further purification and concentration were performed using Amicon Ultra3K (Millipore), thereby obtaining nucleic acid complexes, i.e., nucleic acid complexes 1 to 7 corresponding to compounds 8, 11, 14, 15, 17, 23, 24.

[0263]

[0264] Nucleic acid complex 1

[0265]

[0266] Nucleic acid complex 2

[0267]

[0268] Nucleic acid complex 3

[0269]

[0270] Nucleic acid complex 4

[0271]

[0272] Nucleic acid complex 5

[0273]

[0274] Nucleic acid complex 6

[0275]

[0276] Nucleic acid complex 7

[0277]

[0278] Example 8: Synthesis of Nucleic Acid Complex 8

[0279] Sodium tetraborate buffer (pH 8.5) and compound 28 (120 nmol) dissolved in DMSO were added to SEQ-2 (26.6 nmol) and stirred at room temperature. After adding water to the reaction solution, it was purified using Amicon Ultra 3K (Millipore). 5 times the amount of 28% ammonia water was added to the obtained crude product and allowed to stand at room temperature for 3 hours. After adding water to the reaction solution, it was purified using Amicon Ultra 3K (Millipore). It was further purified by reverse phase HPLC to obtain nucleic acid complex 8.

[0280] Nucleic acid complex 8

[0281]

[0282] Description of nucleic acid sequences

[0283] The sequence of the nucleic acid used in this example (5'-3') is A(F)^G(M)^G(F)A(M)C(F)U(M)G(F)G(M)U(F)C(M)U(F)U(F)U(M)C(F)U(M)A(F)U(M)A(F)U(M)^C(F)^U(M), capital letters represent RNA, (M) represents 2'-O-methyl modified RNA, (F) represents 2'-fluoro RNA, and ^ represents a phosphorothioate bond. In addition, a cyanine dye Cy3 (excitation wavelength 555nm, fluorescence wavelength 570nm) as a fluorescent dye is bound to the 5' end of each oligonucleotide. The molecular weight of the nucleic acid complex synthesized in SEQ-1, 2 and this example was measured using MALDI-TOF-MS, and the results are shown in Table 1.

[0284] [Table 1]

[0285]

[0286] <Test Example 1>

[0287] Evaluation of in vitro uptake activity of nucleic acid complexes into human CD206-expressing Lenti-X 293T cells

[0288] The nucleic acid complexes synthesized in the examples were introduced into human CD206-expressing Lenti-X 293T cells (Clontech) by the following method, and the uptake was evaluated. Human CD206-expressing Lenti-X 293T cells (Clontech) were cultured at a concentration of 2×10 4 Cells were inoculated into 96-well PDL (Poly-D-Lysine) coated plates (Corning) at a concentration of 100 μL / well and cultured in a 5% CO2 incubator at 37°C for 2 days. SEQ-1 or the synthesized nucleic acid complex was added to a final concentration of 100 nmol / L and cultured in a 5% CO2 incubator at 37°C for 2 hours. 4% paraformaldehyde / PBS (Phosphate Buffered Saline) (Wako) containing 10 μg / mL Hoechst (Life Technologies) was added, the cells were fixed at room temperature for 30 minutes, and washed 4 times with PBS. Fluorescence imaging analysis was performed using IN CellAnalyzer 2200 (GE Healthcare), the Cy3 fluorescence intensity in the well was corrected using the number of nuclei, and the average Cy3 fluorescence intensity of each cell was calculated. At this time, the fluorescence intensity of the well to which the nucleic acid SEQ-1 not modified with the sugar ligand was added was set as 1, and the fluorescence intensity of the well to which each nucleic acid complex was added was calculated as a relative value.

[0289] The results are shown in Table 2. From the results, it was found that nucleic acid complex 6 containing GalNac was not efficiently taken up into cells expressing CD206, compared with SEQ-1 not containing a sugar ligand, whereas nucleic acid complexes 1 to 5 containing mannose were efficiently taken up into cells expressing CD206.

[0290] [Table 2]

[0291]

[0292] <Test Example 2>

[0293] Evaluation of in vitro uptake activity of nucleic acid complexes into human ASGR1-expressing Lenti-X293T cells

[0294] The nucleic acid complexes synthesized in the examples were introduced into human ASGR1-expressing Lenti-X293T cells (Clontech) by the following method, and the uptake activity was evaluated. Human ASGR1-expressing Lenti-X293T cells (Clontech) were cultured at 2×10 4The cells were inoculated into a 96-well PDL-coated plate (Corning) at 100 μL / well and cultured in a 5% CO2 incubator at 37°C for 1 or 2 days. SEQ-1 or the synthesized nucleic acid complex was added to a final concentration of 100 nmol / L and cultured in a 5% CO2 incubator at 37°C for 2 hours. The subsequent fluorescence imaging analysis was performed in the same manner as in Experimental Example 1.

[0295] The results are shown in Table 3. From the results, it was found that nucleic acid complexes 1 to 5 containing mannose were not efficiently taken up into ASGR1-expressing cells, compared with SEQ-1 not containing a sugar ligand, whereas nucleic acid complexes 6 to 8 containing GalNac were efficiently taken up into ASGR1-expressing cells.

[0296] [Table 3]

[0297]

[0298] <Test Example 3>

[0299] Evaluation of nucleic acid complex uptake in mouse hepatocytes and Kupffer cells (in vivo evaluation)

[0300] SEQ-1, nucleic acid complexes 3 and 6 were subcutaneously administered to BALB / c mice (n=3) at 1 mg / kg, respectively. Four hours after administration, the liver was perfused, and hepatocytes and Kupffer cells were separated by flow cytometry, and the fluorescence intensity was measured. At this time, the fluorescence intensity of the group administered with SEQ-1 was set to 1, and the fluorescence intensity of each nucleic acid complex administration group was calculated as a relative value.

[0301] The results are shown in Table 4. From the results, it can be seen that nucleic acid complex 3 containing mannose is efficiently absorbed into mouse Kupffer cells reported as CD206 positive, and nucleic acid complex 6 containing GalNac is efficiently absorbed into mouse hepatocytes reported as ASGR1 positive, compared with SEQ-1 not containing a sugar ligand.

[0302] [Table 4]

[0303]

[0304] Synthesis process of compound 37

[0305]

[0306] Synthesis of compound 30

[0307]

[0308] A mixture of hydrazine acetate (1.29 g, 14.06 mmol) and DMF (50 mL) was heated at 50°C. Subsequently, it was cooled in a water bath at 15°C, and α-D-mannose pentaacetate (4.99 g, 12.8 mmol) was added. The obtained solution was stirred in a water bath at 15°C-19°C for 16 hours. Water and EtOAc were added to the mixture for extraction, and the aqueous layer was further extracted with EtOAc. The combined organic layers were washed with saturated brine, dried with anhydrous sodium sulfate and filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using Biotage Isolera (100 g KP-Sil, 20-100% EtOAc / cyclohexane) to obtain compound 30 (4.19 g) as a 9:1 mixture of α and β non-mirror isomers.

[0309] α isomer

[0310] 1 H NMR (600MHz, CDCl3) δppm: 2.00 (s, 3H), 2.05 (s, 3H), 2.11 (s, 3H), 2.16 (s, 3H), 3.00 (d, J = 4.03Hz, 1H), 4.15 (br d,J=10.64Hz,1H),4.22-4.28(m,2H),5.23-5.33(m,3H),5.43(br dd,J=10.27,3.30Hz,1H)

[0311] Synthesis of compound 31

[0312]

[0313] Trichloroacetonitrile (10.48 mL, 104.5 mmol) was added dropwise to a solution of compound 30 (3.64 g, 10.5 mmol) in DCM (218 mL) under nitrogen atmosphere, followed by DBU (0.158 mL, 1.05 mmol). The mixture was stirred at room temperature under nitrogen atmosphere for 2.25 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography using Biotage Isolera (100 g KP-Sil, 0-50% EtOAc / cyclohexane) to obtain compound 31 (4.567 g).

[0314] 1H NMR (600MHz, CDCl3) δppm: 2.01 (s, 3H), 2.07 (s, 3H), 2.08 (s, 3H), 2.20 (s, 3H), 4.14-4.23(m,2H),4.28(dd,J=12.47,4.77Hz,1H),5.38-5.43(m,2H),5.47(br s,1H),6.28(s,1H),8.79(s,1H)

[0315] Synthesis of compound 33

[0316]

[0317] A DCM (90 mL) solution of compound 31 (2.45 g, 4.96 mmol) and N-Cbz-6-amino-hexane-1-ol (1.87 g, 7.45 mmol) was cooled to 2°C (internal temperature), and boron trifluoride diethyl etherate (0.126 mL, 0.993 mmol) was added dropwise under a nitrogen atmosphere. The obtained mixture was stirred at 2°C for 25 minutes, and then stirred at room temperature for 1 hour and 20 minutes. Saturated aqueous sodium bicarbonate solution was added to the mixture for extraction, and the aqueous layer was extracted with DCM. The combined organic layer was washed with saturated brine, filtered with hydrophobic filter paper, and concentrated under reduced pressure. The residue was purified by column chromatography using Biotage Isolera (100 g KP-Sil, 0-100% EtOAc / cyclohexane) to obtain compound 33 (1.37 g).

[0318] 1 H NMR(600MHz, CDCl3)δppm:1.32-1.43(m,4H),1.49-1.53(m,2H),1.56-1.64(m,2H),1.99(s,3H),2.04(s,3H),2.1 0(s,3H),2.15(s,3H),3.20(q,J=6.72Hz,2H),3.40-3.48(m,1H),3.64-3.71(m,1H),3.97(ddd,J=9.90,5.32,2.3 8Hz,1H),4.08-4.12(m,1H),4.28(dd,J=12.29,5.32Hz,1H),4.79(d,J=1.47Hz,2H),5.10(s,2H),5.22(dd,J=3.3 0,1.83Hz,1H),5.28(t,J=9.54Hz,1H),5.34(dd,J=10.64,3.67Hz,1H),7.29-7.33(m,1H),7.36(d,J=4.03Hz,4H)

[0319] Synthesis of compound 34

[0320]

[0321] 10% palladium-carbon (0.293 g, 50% water-containing product) was added to a solution of compound 33 (1.35 g, 2.31 mmol) in IMS (38 mL) under a nitrogen atmosphere, and stirred at room temperature for 1.5 hours under a hydrogen atmosphere. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. A 4N hydrogen chloride 1,4-dioxane solution (0.78 mL, 3.12 mmol) was added to the filtrate, and the mixture was concentrated under reduced pressure to obtain compound 34 (1.06 g).

[0322] 1 H NMR(600MHz,DMSO-d6)δppm:1.30-1.37(m,4H),1.51-1.61(m,4H),1.94(s ,3H),2.03(s,6H),2.11(s,3H),2.72-2.80(m,2H),3.42-3.50(m,1H),3.63 (dt,J=9.72,6.88Hz,1H),3.88-3.96(m,1H),4.06(dd,J=12.10,2.57Hz,1H ),4.15(dd,J=12.29,5.32Hz,1H),4.87(s,1H),5.04-5.15(m,3H),7.80(br s,3H)

[0323] Synthesis of compound 35

[0324]

[0325] HOBt (161 mg, 1.05 mmol) and EDCI (202 mg, 1.05 mmol) were added to a DMF (3 mL) solution of compound 34 (510 mg, 1.05 mmol) and compound 25 (128.4 mg, 0.21 mmol) in sequence. The obtained mixture was stirred at room temperature for 10 minutes, and then DIPEA (0.18 mL, 1.05 mmol) was added. The obtained solution was stirred at room temperature for 22 hours. A DMF (1.5 mL) solution of compound 34 (505.9 mg, 1.04 mmol), HOBt (161 mg, 1.05 mmol) and EDCI (202 mg, 1.05 mmol) were added, and DIPEA (0.18 mL, 1.05 mmol) was added after 10 minutes. The mixture was further stirred for 3 hours. The mixture was purified by preparative HPLC to obtain compound 34 (46.3 mg).

[0326] 1 H NMR(600MHz,DMSO-d6)δppm:1.21-1.45(m,24H),1.49-1.59(m,8H),1.61-1.89(m,8H),1.93 (s,12H),2.01(s,24H),2.10(s,12H),2.07-2.23(m,8H),2.33-2.37(m,2H),2.96-3.08(m,7 H),3.41-3.48(m,4H),3.57-3.65(m,4H),3.88-3.94(m,4H),4.05(dd,J=12.10,1.83Hz,4H) ,4.10-4.20(m,8H),4.85(s,4H),5.06-5.13(m,14H),7.31-7.40(m,6H),7.69-7.94(m,6H);

[0327] LCMS (ESI+): m / z 1164.58 [M+2H] 2+ .

[0328] Synthesis of compound 36

[0329]

[0330] 10% palladium-carbon (11.5 mg, 50% water-containing product) was added to a solution of compound 35 (40.7 mg, 0.02 mmol) in IMS (6 mL) under nitrogen atmosphere, and stirred at room temperature for 2 hours under hydrogen atmosphere. The mixture was filtered through celite (registered trademark) and washed with IMS. The combined filtrate was concentrated under reduced pressure to obtain compound 36 (43.8 mg).

[0331] 1 H NMR(600MHz,DMSO-d6)δppm:1.20-1.44(m,24H),1.51-1.60(m,8H),1.61-1.88(m,8H),1.93(s,12H),2.02(s,12H),2.02(s, 12H),2.10(s,12H),2.12-2.27(m,10H),2.96-3.08(m,7H),3.41-3.48(m,4H),3.58-3.65(m,4H),3.88-3.94(m,4H),4.04(br d,J=10.27Hz,4H),4.09-4.29(m,8H),4.85(s,4H),5.04-5.14(m,12H),7.71-8.01(br m,7H)

[0332] Synthesis of compound 37

[0333]

[0334] Trimethylamine (16.3 μL, 0.12 mmol) was added to a DMF (3 mL) solution of compound 36 (32.8 mg, 0.015 mmol), followed by dropwise addition of pentafluorophenyl trifluoroacetate (10.0 μL, 0.06 mmol), and the obtained mixture was stirred at room temperature for 1.25 hours. The reaction mixture was injected into water, saturated brine was added, and extracted with EtOAc. The organic layer was washed sequentially with a saturated aqueous sodium bicarbonate solution, a 1M aqueous sodium bisulfate solution, and a saturated brine. The organic layer was dried with anhydrous sodium sulfate and filtered, and concentrated under reduced pressure. The residue was wet-triturated with pentane. Then, the solid was dried under reduced pressure at 40°C to obtain compound 37 (36.7 mg).

[0335] 1 H NMR(600MHz,DMSO-d6)δppm:1.20-1.47(m,24H),1.51-1.61(m,8H),1.62-1.91 (m,8H),1.93(s,12H),2.01(s,24H),2.10(s,12H),2.12-2.33(m,8H),2.80(br t,J=6.79Hz,2H),2.96-3.09(m,7H),3.41-3.50(m,4H),3.58-3.65(m,4H),3.91(br s,4H),4.04(br d,J=12.10Hz,4H),4.10-4.28(m,8H),4.85(br s,4H),5.06-5.15(m,12H),7.68-8.03(m,7H);

[0336] LCMS (ESI+): m / z 1202.46 [M+2H] 2+ .

[0337] Synthesis process of compound 44

[0338]

[0339] Synthesis of compound 39

[0340]

[0341] Anhydrous zinc chloride (3.65 g, 26.8 mmol) was weighed into a 250 mL three-necked flask under argon. The flask was dried at 110°C for 1 hour under reduced pressure, and then left to cool overnight under reduced pressure. Then, the flask was filled with argon, and triacetic acid (2S, 3R, 4R, 5R, 6R)-3-acetamide-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl ester (7.85 g, 20.2 mmol), N-Cbz-6-amino-hexane-1-ol (6.74 g, 26.8 mmol) and DCE (85 mL) were added. After the mixture was heated at 70°C (external temperature) under argon for 3 hours, the mixture was cooled and then diluted with ethyl acetate and saturated sodium bicarbonate aqueous solution. The mixture was stirred for 20 minutes, filtered with diatomaceous earth (registered trademark), and washed with ethyl acetate. The combined filtrates were partitioned, and the organic layer was washed with water and then with saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography using CombiFlash (330 g PuriFlash Si, 20-100% EtOAc / cyclohexane) to obtain compound 39 (9.42 g).

[0342] 1 H NMR(400MHz, CDCl3)δppm:1.30-1.43(m,4H),1.45-1.65(m,4H),1.94(s,3H),2.00(s,3H),2.05(s,3H),2. 13(s,3H),3.12-3.29(m,2H),3.48(dt,J=9.63,6.50Hz,1H),3.79-4.02(m,3H),4.06-4.21(m,2H),4.65(br d,J=8.19Hz,1H),4.78-4.93(m,1H),5.06-5.18(m,2H),5.27(dd,J=11.25,3.06Hz,1H),5.34(d,J=2.81Hz,1H),5.77(br d,J=8.44Hz,1H),7.29-7.42(m,5H)

[0343] LCMS (m / z 581 [M+H] + )

[0344] Synthesis of compound 40

[0345]

[0346] To a solution of compound 39 (9.23 g, 15.9 mmol) in IMS (275 mL) was added a 4 M solution of hydrogen chloride in dioxane (5.17 mL, 20.7 mmol) and 10% palladium-carbon (1.895 g, 50% aqueous product) under a nitrogen atmosphere, and stirred at room temperature for 2.5 hours under a hydrogen atmosphere. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. The filtrate was concentrated under reduced pressure to obtain compound 40 (8.07 g).

[0347] 1 H NMR(400MHz,DMSO-d6)δppm:1.22-1.35(m,4H),1.39-1.62(m,4H),1.78(s,3H),1.8 9(s,3H),2.00(s,3H),2.10(s,3H),2.69-2.82(m,2H),3.41-3.47(m,2H),3.64-3.77 (m,1H),3.81-3.93(m,1H),3.95-4.12(m,2H),4.49(d,J=8.56Hz,1H),4.97(dd,J=1 1.25,3.42Hz,1H),5.22(d,J=3.42Hz,1H),7.62-7.80(m,3H),7.86(d,J=9.29Hz,1H)

[0348] LCMS (m / z 447 [M+H] + )

[0349] Synthesis of compound 41

[0350]

[0351] DIPEA (1.215 mL, 6.96 mmol) was added dropwise to a mixture of CTC resin (1.33 mmol / g, 1.31 g, 1.74 mmol), Fmoc-Glu(OtBu)-OH (0.370 g, 0.87 mmol), Fmoc-D-Glu(OtBu)-OH (0.370 g, 0.87 mmol) and DCM (105 mL) in a 250 mL Quickfit (registered trademark) conical flask. The flask was stoppered, mounted on a disk shaker, and shaken at 300 rpm for 2 hours. MeOH (0.7 mL, 17.3 mmol) was added, and the mixture was further shaken for 35 minutes. The mixture was filtered using a 70 mL plastic phase separation cartridge, nitrogen was passed through, and treated with a 20% piperidine solution in DMF (50 mL) for 30 minutes. The solution was drained and the resin was washed with DMF.

[0352] Add a DMF (10 mL) solution of Fmoc-D-Glu-OtBu (0.740 g, 1.74 mmol), N-Fmoc-L-glutamic acid-1-tert-butyl ester (0.740 g, 1.74 mmol) and HBTU (1.253 g, 3.30 mmol) to the resin in the cartridge, and then drop DIPEA (1.22 mL, 6.96 mmol). Pass nitrogen through the mixture and mix for 1 hour. Then, remove the solvent of the solution by nitrogen flow, mix the resin by passing nitrogen, and treat with a 20% piperidine DMF (50 mL) solution for 35 minutes. Drain the solution and wash the resin with DMF.

[0353] To the remaining resin in the cartridge, a DMF (10 mL) solution of 1,5-pentanedioic acid monobenzyl ester (0.580 g, 2.61 mmol) and HBTU (1.253 g, 3.30 mmol) was added dropwise, followed by the addition of DIPEA (1.215 mL, 6.96 mmol). Nitrogen was passed through the mixture for 80 minutes to mix. The solution was discharged, and the resin was washed with DMF and then with MeOH. The resin was then suction dried. The resin was transferred to a 25×150 mm test tube, dried under reduced pressure for 30 minutes, treated with DCM (5 mL) and TFA (5 mL), and shaken on a disk oscillator for 2 hours. The mixture was then filtered through a phase separation cartridge and washed with DCM. The filtrate was concentrated under reduced pressure to obtain compound 41 (0.5859 g).

[0354] 1 H NMR(400MHz,DMSO-d6)δppm:1.68-1.84(m,4H),1.86-2.01(m,2H),2.13-2.23(m,4H),2.23-2.29(m ,2H),2.38(t,J=7.52Hz,2H),4.11-4.22(m,2H),5.09(s,2H),7.29-7.42(m,5H),8.06-8.17(m,2H)

[0355] LCMS (m / z 481 [M+H] + )

[0356] Synthesis of compound 42

[0357]

[0358] To a solution of compound 40 (4.06 g, 8.41 mmol) and compound 41 (0.5821 g, 1.21 mmol) in DMF (8 mL) were added HOBt (1.392 g, 9.09 mmol), EDCI (1.742 g, 9.09 mmol), and then DIPEA (1.587 mL, 9.09 mmol). The mixture was stirred at room temperature for 20 hours. The mixture was purified by preparative HPLC to obtain compound 42 (0.48 g).

[0359] 1 H NMR(600MHz,DMSO-d6)δppm:1.23(br s,12H),1.29-1.40(m,6H),1.40-1.48(m,6H),1.60-1.71(m,2H),1.76(s,9H),1.76-1.87(m ,4H),1.89(s,9H),1.99(s,9H),2.00-2.07(m,2H),2.10(s,9H),2.11-2.15(m,2H),2.18(br t,J=7.15Hz,2H),2.34-2.38(m,2H),2.94-3.07(m,6H),3.36-3.43(m,3H),3.65 -3.73(m,3H),3.82-3.91(m,3H),3.98-4.06(m,9H),4.10-4.20(m,2H),4.48(d, J=8.44Hz,3H),4.97(dd,J=11.19,3.12Hz,3H),5.08(s,2H),5.21(d,J=3.30Hz, 3H),7.30-7.39(m,5H),7.71-7.76(m,1H),7.77-7.85(m,5H),7.87-7.93(m,2H)

[0360] LCMS (m / z 1766 [M+H] + )

[0361] Synthesis of compound 43

[0362]

[0363] To a solution of compound 42 (0.43 g, 0.243 mmol) in IMS (85 mL) was added 10% palladium-carbon (0.158 g, 0.074 mmol, 50% water-containing product) under a nitrogen atmosphere, and stirred at room temperature for 2.75 hours under a hydrogen atmosphere. The mixture was filtered through diatomaceous earth (registered trademark) and washed with IMS. The filtrate was concentrated under reduced pressure, and the residue was dissolved in DCM / EtOH (2:1), filtered through diatomaceous earth (registered trademark), and washed with DCM-EtOH (2:1). The filtrate was concentrated under reduced pressure to obtain compound 43 (0.4252 g).

[0364] 1 H NMR(600MHz,DMSO-d6)δppm:1.18-1.29(m,12H),1.31-1.41(m,6H),1.41-1.49(m,6H),1.62-1.75(m,4H),1.77( s,9H),1.81-1.87(m,2H),1.89(s,9H),1.99(s,9H),2.01-2.08(m,2H),2.10(s,9H),2.12-2.24(m,6H),2.95-3.0 7(m,6H),3.37-3.45(m,3H),3.66-3.73(m,3H),3.82-3.92(m,3H),3.98-4.06(m,9H),4.09-4.20(m,2H),4.49(d ,J=8.44Hz,3H),4.97(dd,J=11.19,2.38Hz,3H),5.21(d,J=3.30Hz,3H),7.73-8.04(m,8H),11.81-12.20(m,1H).

[0365] LCMS (m / z 1676 [M+H] + ).

[0366] Synthesis of compound 44

[0367]

[0368] Triethylamine (0.282 mL, 2.024 mmol) was added dropwise to a DMF (50 mL) solution of compound 43 (0.4239 g, 0.253 mmol) under a nitrogen atmosphere, followed by pentafluorophenyl trifluoroacetate (0.174 mL, 1.012 mmol). The mixture was stirred at room temperature for 1 hour and injected into water. Saturated brine was added to the aqueous layer and extracted with EtOAc. The combined organic layer was washed sequentially with saturated sodium bicarbonate aqueous solution, 1M sodium bisulfate aqueous solution and saturated brine. The organic layer was dried and filtered with anhydrous sodium sulfate, then concentrated under reduced pressure, and EtOAc was added to the obtained residue, and washed with 1M sodium bisulfate aqueous solution and saturated brine. The organic layer was dried and filtered with anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 44 (0.4513 g).

[0369] 1 H NMR(600MHz,DMSO-d6)δppm:1.24(br s,12H),1.31-1.40(m,6H),1.41-1.48(m,6H),1.61-1.73(m,2H),1.76(s,9H),1.79-1 .93(m,13H),1.99(s,9H),2.01-2.06(m,2H),2.10(s,9H),2.11-2.18(m,2H),2.27(br t,J=7.34Hz,2H),2.80(t,J=6.97Hz,2H),2.96-3.07(m,6H),3.37-3.43(m,3H),3.69(dt,J=9.63,6.19Hz,3H),3.82-3.91(m,3H) ),3.98-4.06(m,9H),4.09-4.22(m,2H),4.48(d,J=8.44Hz,3H),4.97(dd,J=11.37,3.30Hz,3H),5.21(d,J=3.30Hz,3H),7.73(br t,J=5.14Hz,1H),7.77-7.85(m,5H),7.91(br dd,J=11.19,7.89Hz,1H),7.98(br d,J=8.07Hz,1H)

[0370] LCMS (m / z 1843.56 [M+H] + )

[0371] Synthesis process of compound 47

[0372]

[0373] Synthesis of compound 45

[0374]

[0375] To a solution of compound 34 (1383 mg, 2.86 mmol) and compound 41 (183.1 mg, 0.381 mmol) in DMF (3.0 mL) were added HOBt (438 mg, 2.86 mmol), EDCI (548 mg, 2.86 mmol) and DIPEA (0.50 mL, 2.86 mmol) in sequence. The resulting mixture was stirred at room temperature for 24 hours. The mixture was purified by preparative HPLC to obtain compound 45 (133.4 mg).

[0376] 1 H NMR(600MHz,DMSO-d6)δppm:1.23-1.34(m,12H),1.34-1.43(m,6H),1.50-1.59(m,6H),1.62-1.72(m,2H),1.74- 1.80(m,2H),1.81-1.89(m,2H),1.93(s,9H),2.01(s,18H),2.03-2.07(m,2H),2.10(s,9H),2.11-2.15(m,2H),2 .16-2.21(m,2H),2.33-2.38(m,2H),2.97-3.07(m,6H),3.41-3.48(m,3H),3.57-3.64(m,3H),3.87-3.94(m,3H) ,4.05(dd,J=12.10,2.57Hz,3H),4.10-4.19(m,5H),4.85(s,3H),5.0-5.13(m,11H),7.29-7.39(m,5H),7.71(br t,J=4.95Hz,1H),7.76-7.84(m,2H),7.85-7.91(m,2H)

[0377] LCMS (m / z 1769 [M+H] + )

[0378] Synthesis of compound 46

[0379]

[0380] 10% palladium-carbon (37.4 mg, 50% aqueous product) was added to a solution of compound 45 (101.9 mg, 0.058 mmol) in IMS (20 mL) under nitrogen atmosphere. The mixture was stirred at room temperature for 2.5 hours under hydrogen atmosphere. The mixture was filtered using diatomaceous earth (registered trademark) and then washed with IMS. The combined filtrate was concentrated under reduced pressure to obtain compound 46 (95.9 mg).

[0381] 1 H NMR(600MHz,DMSO-d6)δppm:1.28(br s,12H),1.34-1.44(m,6H),1.49-1.60(m,6H),1.61-1.76(m,4H),1.81-1.90(m,2H),1.93(s, 9H),2.02(s,9H),2.02(s,9H),2.04-2.08(m,2H),2.10(s,9H),2.12-2.23(m,6H),2.96-3.07( m,6H),3.40-3.48(m,3H),3.57-3.65(m,3H),3.86-3.94(m,3H),4.05(dd,J=12.10,2.38Hz,3H ),4.09-4.18(m,5H),4.85(s,3H),5.01-5.14(m,9H),7.62-8.17(m,5H),11.84-12.15(m,1H).

[0382] LCMS (m / z 1679 [M+H] + ).

[0383] Synthesis of compound 47

[0384]

[0385] Triethylamine (62.8 μL, 0.451 mmol) was added to a DMF (9 mL) solution of compound 46 (94.6 mg, 0.056 mmol) under a nitrogen atmosphere, and pentafluorophenyl trifluoroacetate (38.7 μL, 0.225 mmol) was added dropwise. The obtained mixture was stirred at room temperature for 1 hour. The mixture was injected into water, saturated brine was added, and extracted with EtOAc. The combined organic layer was washed in sequence with saturated sodium bicarbonate aqueous solution, 1M sodium bisulfate aqueous solution and saturated brine. The organic layer was dried with anhydrous sodium sulfate and filtered, and then concentrated under reduced pressure to obtain compound 47 (109.0 mg).

[0386] 1H NMR(600MHz,DMSO-d6)δppm:1.23-1.33(m,12H),1.34-1.43(m,6H),1.50-1.60(m,6H),1.62-1.77( m,2H),1.80-1.91(m,4H),1.93(s,9H),2.01(s,18H),2.03-2.07(m,2H),2.10(s,9H),2.12-2.20(m ,2H),2.25-2.30(m,2H),2.77-2.82(m,2H),2.96-3.08(m,6H),3.41-3.48(m,3H),3.53-3.68(m,3H ),3.86-3.95(m,3H),4.00-4.07(m,3H),4.10-4.23(m,5H),4.85(s,3H)5.04-5.13(m,9H),7.71(br t,J=5.32Hz,1H),7.78-7.85(m,2H),7.89(dd,J=12.84,8.07Hz,1H),7.96(d,J=8.07Hz,1H)

[0387] LCMS (m / z 1845.47 [M+H] + )

[0388] Synthesis process of compounds 53a, 53b and 53c

[0389]

[0390] Synthesis of compound 49a

[0391]

[0392] Zinc chloride (285 mg, 2.09 mmol) placed in a 50 mL three-necked flask was dried at 110 ° C for 1 hour under reduced pressure and allowed to cool overnight under reduced pressure. The flask was purged with nitrogen and a DCE (5 mL) solution of compound 38 (611 mg, 1.57 mmol) and compound 48a (500 mg, 2.09 mmol) was added. The mixture was heated at 70 ° C (external temperature) for 3 hours under a nitrogen environment. The mixture was allowed to cool and diluted with ethyl acetate (10 mL) / saturated sodium bicarbonate aqueous solution (5 mL). The mixture was stirred for 10 minutes, filtered with diatomaceous earth (registered trademark), and washed with ethyl acetate. The combined filtrate was washed with water and saturated brine. The organic layer was filtered with hydrophobic filter paper and concentrated under reduced pressure. The residue was purified by column chromatography using Biotage Isolera (50 g KP-Sil, 0-50% (3:1 EtOAc-IMS) / MTBE), thereby obtaining Compound 49a (599.4 mg).

[0393] 1 H NMR(600MHz, CDCl3)δppm:1.90(s,3H),2.00(s,3H),2.04(s,3H),2.13(s,3H),3.26-3.86(m,8H),3.87-4.00(m,2H),4.05-4.19(m,2H),4.76(br d,J=7.70Hz,1H),5.10-5.20(m,2H),5.26(br dd,J=6.60,3.30Hz,1H),5.32(br s,1H),5.43(br s,1H),5.75(brd,J=7.34Hz,1H),7.28-7.42(m,5H).

[0394] LCMS (m / z 569 [M+H] + ).

[0395] Synthesis of compound 50a

[0396]

[0397] To a solution of compound 49a (594.2 mg, 1.05 mmol) in IMS (18 mL) was added 4M hydrogen chloride in 1,4-dioxane (0.34 mL, 1.36 mmol) and 10% palladium-carbon (50% aqueous, 125 mg) under nitrogen. The mixture was stirred at room temperature for 2.5 hours under hydrogen. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. The combined filtrate was concentrated under reduced pressure to obtain compound 50a (507.9 mg).

[0398] 1 H NMR(600MHz,DMSO-d6)δppm:1.77-1.84(m,3H),1.86-1.92(m,3H),1.97-2.03(m,3H),2.06-2.13(m,3H),2.92-3.00(m, 2H),3.52-3.75(m,5H),3.83(ddd,J=11.28,5.41,3.85Hz,1H),3.86-3.93(m,1H),3.95-4.17(m,3H),4.57(d,J=8.44Hz 1H),4.99(dd,J=11.19,3.48Hz,1H),5.23(d,J=3.67Hz,1H),7.81(br s,3H),7.85-7.92(m,1H)

[0399] LCMS (m / z 435 [M+H] + )

[0400] Synthesis of compound 51a

[0401]

[0402] To a solution of compound 50a (506.5 mg, 1.08 mmol) and compound 41 (68.9 mg, 0.14 mmol) in DMF (2.0 mL) were added HOBt (165 mg, 1.08 mmol), EDCI (206 mg, 1.08 mmol) and DIPEA (188 μL, 1.08 mmol) in sequence. The obtained mixture was stirred at room temperature for 20 hours. The mixture was purified by preparative HPLC to obtain compound 51a (40.0 mg).

[0403] 1H NMR(600MHz,DMSO-d6)δppm 1.62-1.73(m,2H),1.77(s,9H),1.80-1.87(m,2H),1.89(s,9H),1.99(s,9H),2.02-2 .08(m,2H),2.10(s,9H),2.11-2.24(m,4H),2.34-2.38(m,2H),3.13-3.22(m,4H),3. 34-3.42(m,7H),3.44-3.54(m,7H),3.55-3.61(m,3H),3.73-3.80(m,3H),3.84-3.91 (m,3H),3.97-4.08(m,9H),4.13-4.25(m,2H),4.55(dd,J=8.07,3.67Hz,3H),4.99(br d,J=11.00Hz,3H),5.07-5.10(m,2H),5.22(d,J=3.30Hz,3H),7.31-7.40(m,5H),7.60-7.97(m,8H)

[0404] LCMS (m / z 1730 / 1731 [M+H] + )

[0405] Synthesis of compound 52a

[0406]

[0407] 10% palladium-carbon (50% aqueous product, 16.0 mg) was added to a solution of compound 51a (42.7 mg, 0.03 mmol) in IMS (8 mL) under nitrogen atmosphere. The mixture was stirred at room temperature for 2.5 hours under hydrogen atmosphere. The mixture was filtered using celite (registered trademark) and washed with IMS. The filtrate was concentrated under reduced pressure to obtain compound 52a (41.2 mg).

[0408] 1H NMR(600MHz,DMSO-d6)δppm 1.62-1.75(m,4H),1.78(s,9H),1.81-1.87(m,2H),1.89(s,9H),2.00 (s,9H),2.05-2.32(m,17H),3.12-3.23(m,4H),3.36-3.43(m,7H),3. 45-3.54(m,7H),3.55-3.61(m,3H),3.74-3.81(m,3H),3.83-3.92(m, 3H),3.98-4.08(m,9H),4.11-4.23(m,2H),4.51-4.59(m,3H),4.99(br d,J=11.00Hz,3H),5.22(d,J=3.30Hz,3H),7.62-8.04(m,8H)

[0409] LCMS (m / z 1640 / 1641 [M+H] + )

[0410] Synthesis of compound 53a

[0411]

[0412] Triethylamine (28 μL, 0.20 mmol) was added dropwise to a DMF (4 mL) solution of compound 52a (41.6 mg, 0.03 mmol) under a nitrogen atmosphere, followed by pentafluorophenyl trifluoroacetate (17 μL, 0.10 mmol). The obtained mixture was stirred at room temperature for 1.5 hours, injected into water, saturated brine was added, and extracted with EtOAc. The combined organic layer was washed with saturated sodium bicarbonate aqueous solution, 1M sodium bisulfate aqueous solution and saturated brine in sequence. The organic layer was dried with anhydrous sodium sulfate and filtered, and concentrated under reduced pressure. The residue was transferred to a sample bottle containing DCM / MeOH, and after evaporating the solvent, it was dried under reduced pressure at 40°C for 2 hours to obtain compound 52c (27.1 mg).

[0413] 1H NMR(600MHz,DMSO-d6)δppm:1.57-1.75(m,4H),1.77(s,9H),1.86-1.95(m,11H),2.00(s,9H),2.05-2.33(m,15H),2.77-2.88(m,2H),3.11 -3.24(m,4H),3.41-3.54(m,14H),3.55-3.62(m,3H),3.74-3.81(m,3H),3.84-3.91(m,3H),3.98-4.07(m,9H),4.11-4.23(m,2H),4.55(br dd,J=8.07,3.67Hz,3H),4.99(br d,J=11.00Hz,3H),5.22(d,J=3.30Hz,3H),7.65-8.04(m,8H)

[0414] LCMS (m / z 1806.83 [M+H] + )

[0415] Synthesis of compound 49b

[0416]

[0417] Zinc chloride (0.466 g, 3.42 mmol) was placed in a 50 mL three-necked flask and dried at 110 ° C for 95 minutes under reduced pressure, and cooled overnight under reduced pressure. The flask was replaced with nitrogen, and a DCE (10 mL) solution of compound 38 (1.00 g, 2.57 mmol) and compound 48b (0.97 g, 3.42 mmol) was added. The mixture was heated at 70 ° C (external temperature) for 3 hours under a nitrogen environment. The mixture was cooled and diluted with ethyl acetate (20 mL) / saturated sodium bicarbonate aqueous solution (10 mL). The mixture was stirred for 15 minutes, filtered with diatomaceous earth (registered trademark), and washed with ethyl acetate. The filtrate was washed with water and saturated brine. The organic layer was filtered with hydrophobic filter paper and concentrated under reduced pressure. The residue was purified by column chromatography using Biotage Isolera (100 g Sfar Duo Si, 0-50% (3:1 EtOAc-IMS) / MTBE) to obtain Compound 49b (1.14 g).

[0418] 1H NMR (600MHz, CDCl3) δppm: 1.92 (s, 3H), 1.98 (s, 3H), 2.03 (s, 3H), 2.14 (s, 3H), 3. 32-3.50(m,2H),3.53-3.73(m,8H),3.77-3.94(m,3H),4.02-4.22(m,3H),4.74(br d,J=8.44Hz,1H),5.03-5.08(m,1H),5.11(br s,2H),5.26(br s,1H),5.40-5.53(m,1H),6.11-6.21(m,1H),7.30-7.40(m,5H).

[0419] LCMS (m / z 613 [M+H] + ).

[0420] Synthesis of compound 50b

[0421]

[0422] To a solution of compound 49b (1.14 g, 1.86 mmol) in IMS (32 mL) was added a 4M solution of hydrogen chloride in 1,4-dioxane (0.60 mL, 2.42 mmol) and 10% palladium-carbon (50% aqueous, 0.221 g) under nitrogen. The mixture was stirred at room temperature for 2.5 hours under hydrogen. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. The combined filtrate was concentrated under reduced pressure to obtain compound 50b (0.97 g).

[0423] 1 H NMR(600MHz,DMSO-d6)δppm 1.79(s,3H),1.89(s,3H),2.00(s,3H,)2.11(s,3H),2.94-3.02(m,2H),3.50-3.62(m,9H),3.77-3.84(m,1H),3.86-3.94(m ,1H),3.98-4.10(m,3H),4.54(d,J=8.44Hz,1H),4.97(dd,J=11.19,3.48Hz,1H),5.22(d,J=3.67Hz,1H),7.70-7.93(m,4H)

[0424] LCMS (m / z 479 [M+H] + )

[0425] Synthesis of compound 51b

[0426]

[0427] To a DMF (3 mL) solution of compound 50b (556 mg, 1.08 mmol) and compound 41 (74.1 mg, 0.15 mmol) were added HOBt (165 mg, 1.08 mmol), EDCI (207 mg, 1.08 mmol), and DIPEA (189 μL, 1.08 mmol) in sequence. The resulting mixture was stirred at room temperature for 19 hours. The mixture was purified by preparative HPLC to obtain compound 51b (67.5 mg).

[0428] 1 H NMR(600MHz,DMSO-d6)δppm 1.61-1.74(m,2H),1.77(s,9H),1.80-1.85(m,2H),1.89(s,9H),2.00(s,9H),2.03-2.08(m,2H),2.10(s ,9H),2.12-2.24(m,4H),2.35-2.38(m,2H),3.10-3.23(m,4H),3.36-3.42(m,7H),3.44-3.63(m,22H),3. 74-3.81(m,3H),3.83-3.91(m,3H),3.99-4.08(m,9H),4.13-4.25(m,2H),4.55(d,J=8.44Hz,3H),4.95-5 .00(m,3H),5.09(s,2H),5.21(d,J=3.30Hz,3H),7.31-7.41(m,5H),7.72-7.86(m,4H),7.86-7.99(m,4H)

[0429] LCMS (m / z 1862 / 1863 [M+H] + )

[0430] Synthesis of compound 52b

[0431]

[0432] 10% palladium-carbon (50% aqueous product, 23.1 mg) was added to a solution of compound 51b (66.1 mg, 0.04 mmol) in IMS (13 mL) under nitrogen atmosphere. The mixture was stirred at room temperature for 2.5 hours under hydrogen atmosphere. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. The combined filtrate was concentrated under reduced pressure to obtain compound 52b (61.3 mg).

[0433] 1H NMR(600MHz,DMSO-d6)δppm 1.63-1.75(m,4H),1.77(s,9H),1.81-1.87(m,2H),1.89(s,9H),2.00(s,9H),2.03-2.24(m,17H),3.09-3.23(m,4H),3.3 5-3.43(m,7H),3.44-3.64(m,22H),3.74-3.81(m,3H),3.84-3.91(m,3H),3.98-4.07(m,9H),4.10-4.24(m,2H),4.56(br d,J=8.80Hz,3H),4.98(br d,J=11.00Hz,3H),5.22(d,J=2.93Hz,3H),7.70-8.06(m,8H).

[0434] LCMS (m / z 1772 / 1773 [M+H] + )

[0435] Synthesis of compound 53b

[0436]

[0437] Triethylamine (38 μL, 0.27 mmol) was added dropwise to a DMF (6 mL) solution of compound 52b (60.7 mg, 0.03 mmol) under a nitrogen atmosphere, followed by pentafluorophenyl trifluoroacetate (24 μL, 0.14 mmol). The obtained mixture was stirred at room temperature for 77 minutes, injected into water, saturated brine was added, and extracted with EtOAc. The combined organic layer was washed with saturated sodium bicarbonate aqueous solution, 1 M sodium bisulfate aqueous solution, 4% lithium chloride aqueous solution and saturated brine in sequence. The organic layer was dried with anhydrous sodium sulfate and filtered, then concentrated, and dried under reduced pressure at 40°C for 4 hours to obtain compound 53b (29.3 mg).

[0438] 1H NMR(600MHz,DMSO-d6)δppm:1.62-1.75(m,2H),1.77(s,9H),1.85-1.95(m,13H),2.00(s,9H), 2.10(s,9H),2.12-2.33(m,6H),2.78-2.86(m,2H),3.12-3.24(m,4H),3.35-3.44(m,7H),3.45 -3.64(m,22H),3.75-3.81(m,3H),3.83-3.92(m,3H),3.99-4.06(m,9H),4.12-4.26(m,2H),4. 55(d,J=8.44Hz,3H),4.98(dd,J=11.19,2.02Hz,3H),5.21(d,J=3.67Hz,3H),7.64-8.03(m,8H)

[0439] LCMS (m / z 1939.01 [M+H] + )

[0440] Synthesis of compound 49c

[0441]

[0442] Zinc chloride (210 mg, 1.54 mmol) placed in a 50 mL three-necked flask was dried at 110 ° C for 75 minutes under reduced pressure and allowed to cool overnight under reduced pressure. The flask was replaced with nitrogen, and a DCE (5 mL) solution of compound 38 (450.2 mg, 1.16 mmol) and compound 48c (503.4 mg, 1.54 mmol) was added. The mixture was heated at 70 ° C (external temperature) for 3 hours under an argon environment. The mixture was allowed to cool and diluted with ethyl acetate (10 mL) / saturated sodium bicarbonate aqueous solution (5 mL). The mixture was stirred for 15 minutes, filtered with diatomaceous earth (registered trademark), and washed with ethyl acetate. The filtrate was washed with water and saturated brine. The organic layer was filtered with hydrophobic filter paper and concentrated under reduced pressure. The residue was purified by column chromatography using Biotage Isolera (50 g Sfar Si, 0-50% (3:1 EtOAc-IMS) / MTBE) to obtain Compound 49c (469.0 mg).

[0443] 1H NMR (600MHz, CDCl3) δppm: 1.95 (s, 3H), 1.96 (s, 3H), 2.04 (s, 3H), 2.15 (s, 3H), 3.39 (br d,J=4.77Hz,2H),3.52-3.72(m,12H),3.79-3.94(m,3H),4.09-4.14(m,1H),4.14-4.18(m,1H),4.18-4.25(m,1H),4.77(br d,J=8.44Hz,1H),4.98-5.06(m,1H),5.10(br s,2H),5.31(br s,1H),5.34-5.45(m,1H),6.29-6.39(m,1H),7.29-7.33(m,1H),7.36(d,J=4.40Hz,4H)

[0444] LCMS (m / z 657 [M+H] + )

[0445] Synthesis of compound 50c

[0446]

[0447] To a solution of compound 49c (0.45 g, 0.69 mmol) in IMS (12 mL) was added a 4M solution of hydrogen chloride in 1,4-dioxane (225 μL, 0.90 mmol) and 10% palladium-carbon (50% aqueous product, 0.083 g) under nitrogen. The mixture was stirred at room temperature for 2.5 hours under hydrogen. The mixture was filtered using diatomaceous earth (registered trademark) and washed with IMS. The filtrate was concentrated under reduced pressure to obtain compound 50c (0.40 g).

[0448] 1 H NMR(600MHz,DMSO-d6)δppm 1.78(s,3H),1.89(s,3H),2.00(s,3H),2.11(s,3H),2.94-3.01(m,2H),3.48-3.62(m,13H),3.76-3.82(m,1H),3.85- 3.93(m,1H),3.99-4.08(m,3H),4.55(d,J=8.44Hz,1H),4.94-5.01(m,1H),5.22(d,J=3.67Hz,1H),7.75-7.88(m,4H)

[0449] LCMS (m / z 423 [M+H] + )

[0450] Synthesis of compound 51c

[0451]

[0452] To a solution of compound 50c (379.8 mg, 0.679 mmol) and compound 41 (47.2 mg, 0.10 mmol) in DMF (2 mL) were added HOBt (104 mg, 0.68 mmol), EDCI (130 mg, 0.68 mmol) and DIPEA (119 μL, 0.68 mmol) in sequence. The resulting mixture was stirred at room temperature for 19 hours. The mixture was purified by preparative HPLC to obtain compound 51c (53.8 mg).

[0453] 1 H NMR(600MHz,DMSO-d6)δppm 1.61-1.73(m,2H),1.77(s,9H),1.79-1.85(m,2H),1.89(s,9H),2.00(s,9H),2.03-2.08(m,2H),2.10(s,9H),2.1 2-2.22(m,4H),2.33-2.37(m,2H),3.07-3.23(m,4H),3.34-3.42(m,7H),3.43-3.55(m,30H),3.55-3.62(m,4H),3. 75-3.81(m,3H),3.85-3.92(m,3H),3.99-4.07(m,9H),4.13-4.24(m,2H),4.56(d,J=8.80Hz,3H),4.97(dd,J=11.0 0,3.30Hz,3H),5.06-5.11(m,2H),5.21(d,J=3.30Hz,3H),7.30-7.39(m,5H),7.62-7.84(m,5H),7.85-7.95(m,3H)

[0454] LCMS (m / z 1994 / 1995 [M+H] + )

[0455] Synthesis of compound 52c

[0456]

[0457] 10% palladium-carbon (50% aqueous product, 27.3 mg) was added to a solution of compound 51c (84 mg, 0.04 mmol) in IMS (17 mL) under nitrogen atmosphere. The mixture was stirred at room temperature for 2.5 hours under hydrogen atmosphere. The mixture was filtered using celite (registered trademark) and washed with IMS. The filtrate was concentrated under reduced pressure to obtain compound 52c (78.9 mg).

[0458] 1 H NMR(600MHz,DMSO-d6)δppm 1.60-1.75(m,4H),1.78(s,9H),1.80-1.87(m,2H),1.89(s,9H),2.00(s,9H),2.03-2.32(m,17H),3.12-3.23(m,4H),3.3 6-3.42(m,7H),3.43-3.63(m,34H),3.74-3.81(m,3H),3.84-3.92(m,3H),3.99-4.07(m,9H),4.09-4.22(m,2H),4.57(br d,J=8.44Hz,3H),4.98(dd,J=11.19,3.12Hz,3H),5.21(d,J=3.30Hz,3H),7.61-8.05(m,8H),12.01(br s,1H)

[0459] LCMS (m / z 1904 / 1905 [M+H] + )

[0460] Synthesis of compound 53c

[0461]

[0462] Triethylamine (45 μL, 0.33 mmol) was added dropwise to a DMF (3 mL) solution of compound 52c (77.3 mg, 0.04 mmol) under a nitrogen atmosphere, followed by pentafluorophenyl trifluoroacetate (27 μL, 0.16 mmol). The obtained mixture was stirred at room temperature for 1.5 hours, injected into water, saturated brine was added, and then extracted with EtOAc. The organic layer was washed in sequence with a saturated sodium bicarbonate aqueous solution, a 1M sodium bisulfate aqueous solution, and then saturated brine. The organic layer was dried with anhydrous sodium sulfate and filtered, and then concentrated under reduced pressure. The residue was transferred to a sample bottle containing DCM / MeOH, and after evaporating the solvent, it was dried under reduced pressure at 40°C for 2 hours to obtain a residue. It was dissolved in EtOAc (20 mL), washed with a 4% lithium chloride aqueous solution (5 mL) and then with saturated brine (5 mL), dried with anhydrous sodium sulfate and filtered, and then evaporated. The residue was transferred to a sample bottle containing EtOAc, evaporated, and dried under reduced pressure at 40° C. DCM was added to the residue, concentrated under reduced pressure, and the residue was dried under reduced pressure at 40° C. for 4 hours to obtain Compound 53c (19.4 mg).

[0463] 1H NMR(600MHz,DMSO-d6)δppm:1.59-1.73(m,2H),1.77(s,9H),1.85-1.95(m,13H),2.00(s,9H), 2.10(s,9H),2.12-2.34(m,6H),2.77-2.89(m,2H),3.11-3.23(m,4H),3.35-3.44(m,7H),3.45- 3.63(m,34H),3.75-3.80(m,3H),3.84-3.91(m,3H),4.00-4.07(m,9H),4.16-4.26(m,2H),4.5 6(d,J=8.80Hz,3H), 4.97(dd,J=11.37,3.30Hz,3H), 5.21(d,J=3.67Hz,3H), 7.62-8.03(m,8H).

[0464] QC LCMS (m / z 1035.97 [M+2H] 2+ )

[0465] Examples 9 to 12: Synthesis of Nucleic Acid Complexes 9 to 12

[0466] Sodium tetraborate buffer (pH 8.5) and compound 28 or 44 (1000 nmol) dissolved in DMSO were added to the positive sense chain (215 nmol) of the B2M (β2-microglobulin) target siRNA, and the mixture was stirred at room temperature. After adding water to the reaction solution, purification was performed using Vivaspin3K (Sartorius). A 5-fold amount of 28% ammonia water was added to the obtained crude product, and the mixture was allowed to stand at room temperature for 2 hours. After adding water to the reaction solution, purification was repeated using Vivaspin3K (Sartorius) to obtain nucleic acid complexes 9 to 12. The molecular weight of the nucleic acid complex synthesized in this example was measured by ESI-MS or MALDI-TOF-MS. The sequence of the positive sense chain, the sequence of the antisense chain and the molecular weight used are shown in Table 5.

[0467] [Table 5]

[0468]

[0469] Table 6 shows the sequence and molecular weight of the nucleic acid complex.

[0470] [Table 6]

[0471]

[0472] Nucleic acid complex 9

[0473]

[0474] Nucleic acid complex 10

[0475]

[0476] Nucleic acid complex 11

[0477]

[0478] Nucleic acid complex 12

[0479]

[0480] Examples 13 to 16: Preparation of Nucleic Acid Complexes 13 to 16 (si-RNA)

[0481] The antisense strand (siB2M-as) and nucleic acid complexes 9 to 12 were added in equimolar amounts to prepare si-RNA targeting B2M. Table 7 shows the sense strand and antisense strand of si-RNA.

[0482] [Table 7]

[0483]

[0484] <Test Example 4>

[0485] The nucleic acid complex (si-RNA) prepared in Examples 13 to 16 was subcutaneously administered to BALB / c mice (3 mice per group) at 1.0 mg / kg or 5.0 mg / kg, and the liver was removed 7 days after administration. The mRNA expression levels of B2M in the liver and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as an internal control were measured by qPCR (quantitative polymerase chain reaction) using a TaqMan probe (Applied Biosystems). The B2M mRNA expression level in the liver of mice in the untreated group (control group) was set to 100%, and the B2M mRNA expression level (relative value) of the nucleic acid complex administration group was calculated. The results are shown in Table 8.

[0486] [Table 8]

[0487]

[0488] According to the results shown in Table 8, siRNA-2, siRNA-3, siRNA-4 and siRNA-5 showed a dose-dependent gene expression inhibitory effect. In contrast, siRNA-1 without a sugar ligand showed almost no gene expression inhibitory effect at 5.0 mg / kg, while siRNA containing a sugar ligand showed a high gene expression inhibitory effect at 1.0 mg / kg.

[0489] Examples 17 to 19: Synthesis of Nucleic Acid Complexes 17 to 19

[0490] Nucleic acid complexes were prepared in the same manner as in Examples 9 to 11 except that a Gapmer-type LNA antisense nucleic acid (ASO; ISIS-549148) having a 3-10-3 structure was used as the nucleic acid and Compound 44, 47 or 53a was used. The sequences of the sense strand and antisense strand used and their molecular weights are shown in Table 9.

[0491] [Table 9]

[0492]

[0493] 5(L): LNA 5-methylcytosine; 5(x) = DNA 5-methylcytosine

[0494] Table 10 shows the sequences and molecular weights of the nucleic acid complexes.

[0495] [Table 10]

[0496]

[0497] Nucleic acid complex 17

[0498]

[0499] Nucleic acid complex 18

[0500]

[0501] Nucleic acid complex 19

[0502]

[0503] <Test Example 5>

[0504] Evaluation of in vitro uptake activity of nucleic acid complexes into human CD206-expressing Lenti-X 293T cells

[0505] Nucleic acid complexes 17 to 19 were evaluated in the same manner as in Test Example 1. In Test Example 5, the fluorescence intensity of the well to which the nucleic acid ASO_3'Cy3 not modified with sugar ligand was added was set as 1, and the fluorescence intensity of the well to which each nucleic acid complex was added was calculated as a relative value.

[0506] The results are shown in Table 11. From the results, it was found that nucleic acid complexes 17 and 19 containing GalNac were not efficiently taken up into cells expressing CD206, compared with nucleic acid ASO_3'Cy3 not containing a sugar ligand, whereas nucleic acid complex 18 containing mannose was efficiently taken up into cells expressing CD206.

[0507] [Table 11]

[0508]

[0509] <Test Example 6>

[0510] Evaluation of in vitro uptake activity of nucleic acid complexes into human ASGR1-expressing Lenti-X293T cells

[0511] Nucleic acid complexes 17 to 19 were evaluated in the same manner as in Test Example 2. In Test Example 6, the fluorescence intensity of the well to which the nucleic acid ASO_3'Cy3 not modified with sugar ligand was added was set as 1, and the fluorescence intensity of the well to which each nucleic acid complex was added was calculated as a relative value.

[0512] The results are shown in Table 12. The results show that, compared with the nucleic acid ASO_3'Cy3 not modified with a sugar ligand, the nucleic acid complex 18 containing mannose was not efficiently taken up into the ASGR1-expressing cells, whereas the nucleic acid complexes 17 and 19 containing GalNac were efficiently taken up into the ASGR1-expressing cells.

[0513] [Table 12]

[0514]

Claims

1. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (III): Z is a group containing an oligonucleotide.

2. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (IV): Z is a group containing an oligonucleotide.

3. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (V): Z is a group containing an oligonucleotide.

4. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VI): Z is a group containing an oligonucleotide.

5. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VII): Z is a group containing an oligonucleotide.

6. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (VIII): Z is a group containing an oligonucleotide.

7. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (IX): Z is a group containing an oligonucleotide.

8. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (X): Z is a group containing an oligonucleotide.

9. A nucleic acid complex or a pharmaceutically acceptable salt thereof, wherein the nucleic acid complex is represented by the following formula (XI): Z is a group containing an oligonucleotide. 10 . The nucleic acid complex or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the oligonucleotide is a single strand. The nucleic acid complex or a pharmaceutically acceptable salt thereof according to claim 10 , wherein the oligonucleotide is bound via the 3′ end. 12 . The nucleic acid complex or a pharmaceutically acceptable salt thereof according to claim 10 , wherein the oligonucleotide is bound via the 5′ end. 13 . The nucleic acid complex or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 , wherein the oligonucleotide is double-stranded. The nucleic acid complex or a pharmaceutically acceptable salt thereof according to claim 13 , wherein the oligonucleotide is bound via the 3′ end of one chain. The nucleic acid complex or a pharmaceutically acceptable salt thereof according to claim 13 , wherein the oligonucleotide is bound via the 5′ end of one chain. 16 . A pharmaceutical composition comprising the nucleic acid complex according to claim 1 or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to claim 16 , which regulates the expression of a target gene in a cell.

18. The pharmaceutical composition according to claim 17, wherein the cells are dendritic cells, macrophages or hepatocytes.